WO2009047770A2 - Cytoplasmic malate dehydrogenase (mdh1) targeted treatment for neurodegenerative diseases - Google Patents

Cytoplasmic malate dehydrogenase (mdh1) targeted treatment for neurodegenerative diseases Download PDF

Info

Publication number
WO2009047770A2
WO2009047770A2 PCT/IL2008/001351 IL2008001351W WO2009047770A2 WO 2009047770 A2 WO2009047770 A2 WO 2009047770A2 IL 2008001351 W IL2008001351 W IL 2008001351W WO 2009047770 A2 WO2009047770 A2 WO 2009047770A2
Authority
WO
WIPO (PCT)
Prior art keywords
protein
agent
malate dehydrogenase
mutant
hsodl
Prior art date
Application number
PCT/IL2008/001351
Other languages
French (fr)
Other versions
WO2009047770A3 (en
Inventor
Nava Zisapel
Yael Mali
Original Assignee
Ramot At Tel Aviv University Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot At Tel Aviv University Ltd. filed Critical Ramot At Tel Aviv University Ltd.
Priority to EP08837074A priority Critical patent/EP2180899A2/en
Priority to US12/682,120 priority patent/US8461297B2/en
Priority to CN200880111245A priority patent/CN101820897A/en
Publication of WO2009047770A2 publication Critical patent/WO2009047770A2/en
Publication of WO2009047770A3 publication Critical patent/WO2009047770A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90283—Oxidoreductases (1.) acting on superoxide radicals as acceptor (1.15)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/904—Oxidoreductases (1.) acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Definitions

  • the present invention relates to agents including peptides and small molecules capable of preventing interactions between cytoplasmic malate dehydrogenase and disease causing proteins, useful in the treatment of neurodegenerative disorders and methods of screening thereof.
  • ALS Amyotrophic lateral sclerosis
  • hSODl human copper-zinc superoxide dismutase
  • ROS reactive oxygen species
  • Malate dehydrogenases (MDH, L-malate:NAD oxidoreductase, IUBMB Enzyme Nomenclature EC 1.1.1.37) play an important role in mitochondrial respiration. Specifically, they catalyze the NAD/NADH-dependent interconversion of malate and oxaloacetate in the cytoplasm (cytMDH) and mitochondria (MitMDH). This reaction plays a key part in the malate/aspartate shuttle between the cytoplasm across the mitochondrial membrane, and in the tricarboxylic acid cycle within the mitochondrial matrix.
  • MDH malate dehydrogenase
  • Korolainen et al. discloses increased amounts of mitochondrial glutamate dehydrogenase and cytosolic malate dehydrogenase in AD brains. Furthermore, Korolainen teach that these two enzymes exhibit a significantly decreased degree of oxidation in AD brains compared to controls. [Korolainen et al. Neurobiol Aging. 2006:27;42-53].
  • the present invention provides compositions and methods of treating ALS and neurodegenerative disorders in a subject, comprising an agent .capable of reducing or inhibiting an interaction between a malate dehydrogenase (MDH) protein and a neurodegenerative disease causing protein such as an SODl mutant protein.
  • MDH malate dehydrogenase
  • the present invention also provides methods of identifying an agent capable of treating ALS, comprising testing candidate agents for the ability to disrupt or prevent formation of a malate dehydrogenase complex with a conformationally altered or mutant neurodegenerative disease-causing protein.
  • the present invention is based in part on the unexpected finding that a cytoplasmic enzyme, malate dehydrogenase, forms a complex with specific mutant proteins associated with neurodegenerative processes.
  • the present invention is exemplified by specific MDHl -derived peptides comprising the interacting motif that compete with MDHl for the interaction site.
  • the present invention provides a method of treating ALS in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an agent capable of reducing an interaction between malate dehydrogenase and an SODl protein, thereby treating ALS.
  • the target SODl protein is a mutant SODl protein.
  • the mutant SODl protein is associated with amyotrophic lateral sclerosis (ALS).
  • the agent is a peptide.
  • the agent is a peptide derived from the sequence of a MDH protein.
  • the present invention provides a method of treating a neurodegenerative disorder, the method comprising administering to an individual in need thereof a therapeutically effective amount of an agent capable of increasing brain mitochondrial respiration, thereby treating the neurodegenerative disorder, with the proviso that said agent is not pyruate or oxaloacetate.
  • the agent is capable of increasing cytoplasmic malate dehydrogenase activity in a subject in need thereof.
  • the agent is capable of increasing cytoplasmic malate levels in a subject in need thereof.
  • the agent is a peptide agent.
  • the peptide agent comprises at least 4-7 consecutive amino acids of human malate dehydrogenase.
  • the peptide agent comprises at least 8-18 contiguous amino acids of human malate dehydrogenase.
  • the agent comprises the sequence set forth in SEQ ID NO: 1, corresponding to amino acids 217-239 of the cytMDH protein SWLKGEFITTVQQRGAAVIKARK (SEQ ID NO: 1). Each possibility represents a separate embodiment of the present invention.
  • the agent of methods and compositions of the present invention is, in certain embodiments, a peptide.
  • the peptide comprises a fragment of a malate dehydrogenase protein.
  • the malate dehydrogenase protein is a cytosolic malate dehydrogenase protein (cytMDH).
  • the malate dehydrogenase protein is a cytMDH malate dehydrogenase protein isoform.
  • the malate dehydrogenase protein is a human malate dehydrogenase protein.
  • the malate dehydrogenase protein is a human cytMDH protein isoform.
  • the malate dehydrogenase is any other malate dehydrogenase known in the art. Each possibility represents a separate embodiment of the present invention.
  • the present invention provides a fragment of G93A- hSODl of 19-50 amino acids in length, the peptide comprising the sequence set forth in SEQ ID NO: 1.
  • the G93A-hSODl fragment is 19-45 amino acids in length.
  • the G93A-hSODl fragment is 19-40 amino acids in length.
  • the G93A-hSODl fragment is 19-35 amino acids in length.
  • the G93A-hSODl fragment is 19-30 amino acids in length.
  • the G93A-hSODl fragment is 19-25 amino acids in length.
  • the G93A-hSODl fragment is 25-45 amino acids in length.
  • the G93A-hSODl fragment is 25-40 amino acids in length. In another embodiment, the G93A-hSODl fragment is 25-35 amino acids in length. In another embodiment, the G93A-hSODl fragment is 25-30 amino acids in length.
  • a peptide of the present invention has the sequence set forth in SEQ ID NO: 1. Each possibility represents a separate embodiment of the present invention.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and as an active ingredient, a peptide agent capable of preventing an interaction between malate dehydrogenase and a mutant SODl protein, wherein said mutant SODl protein is associated with an amyotrophic lateral sclerosis (ALS).
  • ALS amyotrophic lateral sclerosis
  • the present invention provides a method of identifying an agent capable of treating ALS, the method comprising the steps of (a) contacting said agent with a preparation of a complex of a malate dehydrogenase protein and a mutant SODl protein, wherein said mutant SODl protein is associated with amyotrophic lateral sclerosis (ALS); and measuring an amount of the complex in the presence of the agent, whereby, if said amount of the complex in the presence of the agent is less than the initial amount, then said agent is capable of treating amyotrophic lateral sclerosis.
  • ALS amyotrophic lateral sclerosis
  • the present invention provides a method of identifying an agent capable of treating ALS, the method comprising the steps of: (a) contacting a malate dehydrogenase protein with a mutant SODl protein, wherein the mutant SODl protein is associated with amyotrophic lateral sclerosis (ALS), in the presence of the agent; (b) measuring the amount of complex formation between the malate dehydrogenase protein and the mutant SODl protein, following step (a); c) contacting the malate dehydrogenase protein with the mutant SODl protein in the absence of the agent; and d) measuring the amount of complex formation between the malate dehydrogenase protein and the mutant SODl protein, following step (c), whereby, if the amount of step (b) is less than the amount of step (d), then the agent is capable of treating amyotrophic lateral sclerosis.
  • ALS amyotrophic lateral sclerosis
  • a complex of the present invention is fluorescently labeled.
  • the step of measuring an amount of a malate dehydrogenase-mutant SODl complex is performed by measuring a signal from the complex.
  • the signal is fluorescence signal.
  • the signal is a FRET signal.
  • an alteration in the signal is measured following addition of the test agent.
  • the present invention provides methods readily generalizable by one skilled in the art to any type of quantitative or semi-quantitative signal that can be engineered depend on an intact malate dehydrogenase-mutant SODl complex. Each possibility represents a separate embodiment of the present invention.
  • Figure 1 FACS analysis of A) G93A-hSODl-GFP expressing NSC-34 cells transfected with BFP-GFP chimera expression plasmid; B) NSC-34 cells transfected with BFP-GFP chimera expression plasmid; and C) G93A-hSODl-GFP expressing NSC-34 cells transfected with BFP expression plasmid. Excitation-UV light; Emission- 530nm.
  • Figure 2. A) Emission spectra obtained upon excitation at 405nm of cells expressing G93A-hSODl-CFP and YFP-tagged candidate protein (data set A). The FRET-related YFP emission (Fig.
  • 2C-F405) was extracted by subtracting the CFP spectrum collected from control cells expressing the G93A-hSODl-CFP alone (Fig. 2C, data set B).
  • FIG. 3 Co-immunoprecipitation of cytMDH with hSODl.
  • NSC-34 cells were co-transfected with YFP-cytMDH and untagged WT-hSODl or untagged G93A-hSODl solubilized 48h later and subjected to immunoprecipitation with anti- hSODl antibodies.
  • B Western blot of YFP-cytMDH and hSODl derivatives in the immunoprecipitated proteins.
  • FIG. 4 MDH activity of the YFP-cytMDH construct.
  • NSC-34 cells were transfected with YFP-MDH (black circles) or YFP (blank circles) expression plasmids. After 48 hours cells were lysed and aliquots containing 25 ⁇ g protein were removed for assessment of MDH activity as measured by the decrease in NADH (OD
  • FIG. 5 WT-hSODl-GFP and G93A-hSODl-GFP cells were treated for 48h with vehicle (non-induced) or doxycycline (induced) to induce hSODl expression.
  • FIG. 6 WT-hSODl-GFP and G93A-hSODl-GFP cells were treated for 48h with vehicle (non-induced) or doxycycline (induced) to induce hSODl expression.
  • Malate (A) and Lactate (B) levels were assessed in solubilized cells and expressed in mg/mg cell protein. * indicates p ⁇ 0.05 compared to non-induced control.
  • Figure 7 WT-hSODl-GFP and G93A-hSODl-GFP cells were treated for 48h with vehicle (non-induced) or doxycycline (induced) to induce hSODl expression.
  • Cytosol (A) and mitochondrial (B) fractions were prepared and analyzed for NAD + and NADH contents. Results were normalized per protein content of the samples. ** indicates p ⁇ 0.01 compared to non-induced control.
  • Figure 8 Model of malate dehydrogenase. The identified peptide is highlighted in yellow, the monomeric units of MDHl are in blue and green. NADH is represented in sticks and balls model.
  • Figure 9 FACS analysis of A) NSC-34 cells transfected with G93A-hSODl- CFP plasmid and YFP-expressing plasmid (negative FRET control). B) NSC-34 cells transfected with G93A-hSODl-CFP and cytMDH-YFP expression plasmids (positive
  • NSC-34 cells co-transfected with G93A-hSODl-CFP /cytMDH- YFP expression plasmids and myc-tagged peptide 14-27 expression plasmid (positive FRET).
  • Figure 10 Effect of peptide 217-239 on cell survival in rotenone- challenged WT-hSODl-GFP- and G93A-hSODl-GFP-expressing NSC-34 cells.
  • Figure 11 Effects of octanoic acid on cell survival in rotenone-challenged WT-hSODl-GFP- and G93A-hSODl-GFP-expressing NSC-34 cells.
  • the present invention provides methods of treating neurodegenerative disorders such as ALS in a subject, comprising the step of administering to the subject an agent capable of reducing an interaction between a malate dehydrogenase protein and an SODl protein.
  • the present invention also provides methods of identifying an agent capable of treating ALS, comprising testing agents for ability to disrupt or prevent formation of a malate dehydrogenase-SODl complex, and methods of treating neurodegenerative disorders that are caused by complex formation of other a conformationally altered or mutant neurodegenerative disease-causing proteins with cytosolic malate dehydrogenase.
  • the present invention provides a method of treating a neurodegenerative disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an agent capable of reducing an interaction between malate dehydrogenase and a conformationally altered or mutant protein, thereby treating a neurodegenerative disorder caused by complex formation of cytosolic malate dehydrogenase with a conformationally altered or mutant-causing protein.
  • the neurodegenerative disorder is amyotrophic lateral sclerosis (ALS).
  • the conformationally altered or mutant protein is a mutant SODl protein.
  • the mutant SODl protein is associated with ALS.
  • the agent is a peptide.
  • the agent is any peptide of the present invention.
  • the present invention provides a method of treating a neurodegenerative disorder, the method comprising administering to an individual in need thereof a therapeutically effective amount of an agent capable of increasing brain mitochondrial respiration, thereby treating the neurodegenerative disorder, with the proviso that said agent is not pyruate or oxaloacetate.
  • the agent is capable of increasing cytoplasmic malate levels in a subject in need thereof.
  • the agent is a peptide agent.
  • the peptide agent comprises at least 4 amino acids of human malate dehydrogenase.
  • the agent comprises the sequence set forth in SEQ ID NO: 1.
  • the agent is any peptide of the present invention. Each possibility represents a separate embodiment of the present invention.
  • the agent of methods and compositions of the present invention is, in another embodiment, a peptide.
  • the peptide comprises a fragment of a malate dehydrogenase protein.
  • the malate dehydrogenase is a human malate dehydrogenase.
  • the malate dehydrogenase is any other malate dehydrogenase known in the art.
  • Each possibility represents a separate embodiment of the present invention.
  • the ALS or neurodegenerative disorder treated by methods and compositions of the present invention is, in another embodiment, associated with a mutation in the gene encoding the human copper-zinc superoxide dismutase (hSODl) protein.
  • the ALS or neurodegenerative disorder is caused by a mutation in the hSOD gene.
  • the hSOD mutation is a gain-of-function mutation.
  • the hSOD mutation is a toxic gain-of-function mutation.
  • the ALS or neurodegenerative disorder is of unknown etiology.
  • the fragment of malate dehydrogenase is 4 amino acids in length. In another embodiment, the fragment is at least 3 amino acids in length. In another embodiment, the fragment is at least 5 amino acids in length. In another embodiment, the fragment is at least 6 amino acids in length. In another embodiment, the fragment is at least 7 amino acids in length. In another embodiment, the fragment is at least 8 amino acids in length. In another embodiment, the fragment is at least 9 amino acids in length. In another embodiment, the fragment is at least 10 amino acids in length. In another embodiment, the fragment is at least 15 amino acids in length. In another embodiment, the fragment is at least 20 amino acids in length. In another embodiment, the fragment is at least 30 amino acids in length. In another embodiment, the fragment is at least 40 amino acids in length. Each possibility represents a separate embodiment of the present invention.
  • the peptide comprises at least 4 consecutive amino acids of a malate dehydrogenase protein. In another embodiment, the peptide comprises at least 3 consecutive amino acids of a malate dehydrogenase protein. In another embodiment, the peptide comprises at least 5 consecutive amino acids of a malate dehydrogenase protein. In another embodiment, the peptide comprises at least 6 consecutive amino acids of a malate dehydrogenase protein. In another embodiment, the peptide comprises at least 7 consecutive amino acids of a malate dehydrogenase protein. In another embodiment, the peptide comprises at least 8 consecutive amino acids of a malate dehydrogenase protein.
  • the peptide comprises at least 9 consecutive amino acids of a malate dehydrogenase protein. In another embodiment, the peptide comprises at least 10 consecutive amino acids of a malate dehydrogenase protein. In another embodiment, the peptide comprises at least 15 consecutive amino acids of a malate dehydrogenase protein. In another embodiment, the peptide comprises at least 20 consecutive amino acids of a malate dehydrogenase protein. In another embodiment, the peptide comprises at least 30 consecutive amino acids of a malate dehydrogenase protein. In another embodiment, the peptide comprises at least 40 consecutive amino acids of a malate dehydrogenase protein. Each possibility represents a separate embodiment of the present invention.
  • a non-limiting example of a mutant SODl protein associated with ALS is G93A-hSODl.
  • the mutant SODl protein is any other mutant SODl protein associated with ALS known in the art.
  • the present invention provides methods readily generalizable by one skilled in the art to treatment of a neurodegenerative disorder such as ALS caused by any mutant SODl protein, particularly a mutant SODl that associates with MDH.
  • the mutant SODl protein causing the disease need not be the same as that used in testing the agent. Since many mutant SODl proteins will interact with MDH in substantially the same manner, the same agents can be used for different mutant SODl proteins.
  • Each possibility represents a separate embodiment of the present invention.
  • the peptide comprises the dimerization site of MDHl with an SODl protein. In another embodiment, the peptide overlaps the dimerization site of MDHl with an SODl protein. In another embodiment, the peptide falls within the dimerization site of MDHl with an SODl protein. In another embodiment, the SODl protein is a mutant SODl protein. In another embodiment, the mutant SODl protein is associated with ALS.
  • the dimerization site of MDHl with G93A-hSODl is depicted herein in Figure 8. Each possibility represents a separate embodiment of the present invention.
  • the peptide comprises the dimerization site of MDHl with another neurodegenerative disease-causing protein. In another embodiment, the peptide overlaps the dimerization site of MDHl with a neurodegenerative disease- causing protein. In another embodiment, the peptide falls within the dimerization site of MDHl with another neurodegenerative disease-causing protein. In another embodiment, the other neurodegenerative disease causing protein is a conformationally altered or mutant protein. In another embodiment, the conformationally altered or mutant protein is associated with a neurodegenerative disorder. Each possibility represents a separate embodiment of the present invention.
  • the present invention provides a fragment of MDH of 19-50 amino acids in length, the peptide comprising the sequence set forth in SEQ ID NO: 1.
  • the MDH fragment is 19-45 amino acids in length.
  • the MDH fragment is 19-40 amino acids in length.
  • the MDH fragment is 19-35 amino acids in length.
  • the MDH fragment is 19-30 amino acids in length.
  • the MDH fragment is 19-25 amino acids in length.
  • the MDH fragment is 25-45 amino acids in length.
  • the MDH fragment is 25-40 amino acids in length.
  • the MDH fragment is 25-35 amino acids in length.
  • the MDH fragment is 25-30 amino acids in length.
  • an MDH-derived peptide of the present invention is derived from wt MDH.
  • the peptide is derived from a mutant MDH.
  • a peptide that disrupts a MDH1-G93A- hSODl complex is a peptide with a sequence set forth in SEQ ID NO: 1.
  • a peptide of methods and compositions of the present invention comprises the sequence set forth in SEQ ID NO: 1.
  • a peptide of methods and compositions of the present invention has the sequence set forth in SEQ ID NO: 1.
  • the peptide overlaps the sequence set forth in SEQ ID NO: 1.
  • the overlap is at least 10 amino acids in length.
  • the overlap is at least 8 amino acids in length.
  • the overlap is at least 6 amino acids in length.
  • the overlap is at least 12 amino acids in length.
  • the overlap is at least 14 amino acids in length.
  • the overlap is at least 16 amino acids in length.
  • the overlap is at least 18 amino acids in length.
  • Each possibility represents a separate embodiment of the present invention.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as an active ingredient, an agent capable of preventing an interaction between malate dehydrogenase and a conformationally altered or mutant protein, wherein the conformationally altered or mutant protein is associated with a neurodegenerative disorder.
  • the neurodegenerative disorder is amyotrophic lateral sclerosis (ALS).
  • the conformationally altered or mutant protein is an SODl protein.
  • the agent is a peptide agent.
  • the agent of methods and compositions of the present invention is a small molecule.
  • the small molecule is selected from the group consisting of malate, octanoate, ⁇ -ketoglutarate, succinate and fumarate.
  • the small molecule is any other small molecule known in the art that is capable of up-regulating an activity of malate dehydrogenase.
  • the malate dehydrogenase is a cytosolic malate dehydrogenase.
  • the small molecule is any other small molecule known in the art that is capable of up-regulating acetyl coenzyme A. Each possibility represents a separate embodiment of the present invention.
  • the conformationally altered or mutant protein is associated with Parkinson's Disease.
  • the protein is Alpha-synuclein.
  • the protein is Parkin.
  • the protein is PINKl .
  • the protein is DJ-I.
  • the protein is ATPl 3 A2.
  • the protein is another protein for which mutations have been linked to Parkinson's disease.
  • the conformationally altered or mutant protein is associated with Alzheimer's disease.
  • the protein is amyloid beta peptide (ABETA).
  • the protein is another protein for which mutations have been linked to Alzheimer's disease. Each possibility represents a separate embodiment of the present invention.
  • the conformationally altered or mutant protein is a protein known to contain poly-glutamine repeats.
  • the protein is Huntingtin, for which mutations of its gene are known to be associated with Huntington disease.
  • the protein is androgen receptor, for which mutations of its gene are known to be associated with Kennedy disease (also known as spinal and bulbar muscular atrophy).
  • Kennedy disease also known as spinal and bulbar muscular atrophy.
  • the conformationally altered or mutant protein is microtubule-associated protein tau. Mutations of the gene encoding tau have been linked to Alzheimer's and other neurodegenerative diseases, such as Pick's disease
  • PID progressive supranuclear palsy
  • CBD corticobasal degeneration
  • FTDP-17 frontotemporal dementia and parkinsonism linked to chromosome 17
  • the present invention provides a method of identifying an agent capable of treating amyotrophic lateral sclerosis (ALS), the method comprising the steps of (a) contacting said agent with a known initial amount of a complex of a malate dehydrogenase protein and a mutant SODl protein, wherein said mutant SODl protein is associated with ALS; and measuring an amount of said complex in the presence of said agent, whereby, if said amount of said complex in the presence of said agent is less than said known initial amount, then said agent is capable of treating amyotrophic lateral sclerosis.
  • ALS amyotrophic lateral sclerosis
  • the present invention provides a method of identifying an agent capable of treating ALS, the method comprising the steps of: (a) contacting a malate dehydrogenase protein with a mutant SODl protein, wherein the mutant SODl protein is associated with ALS, in the presence of the agent; (b) measuring the amount of complex formation between the malate dehydrogenase protein and the mutant SODl protein, following step (a); (c) contacting the malate dehydrogenase protein with the mutant SODl protein in the absence of the agent; and (d) measuring the amount of complex formation between the malate dehydrogenase protein and the mutant SODl protein, following step (c), whereby, if the amount of step (b) is less than the amount of step (d), then the agent is capable of treating amyotrophic lateral sclerosis.
  • the present invention provides a method of identifying an agent capable of treating Parkinson's disease, the method comprising the steps of: (a) contacting a malate dehydrogenase protein with a mutant protein associated with Parkinson's disease, in the presence of the agent; (b) measuring the amount of complex formation between the malate dehydrogenase protein and the mutant protein, following step (a); (c) contacting the malate dehydrogenase protein with the mutant protein in the absence of the agent; and (d) measuring the amount of complex formation between the malate dehydrogenase protein and the mutant protein, following step (c), whereby, if the amount of step (b) is less than the amount of step (d), then the agent is capable of treating Parkinson's disease.
  • the mutant protein is Alpha-synuclein. In another embodiment, the mutant protein is Parkin. In another embodiment, the mutant protein is PINKl. In another embodiment, the mutant protein is DJ-I. In another embodiment, the mutant protein is ATP13A2. In another embodiment, the mutant protein is any other mutant protein known to be associated with Parkinson's disease. Each possibility represents a separate embodiment of the present invention.
  • the present invention provides a method of identifying an agent capable of treating Alzheimer's disease, the method comprising the steps of: (a) contacting a malate dehydrogenase protein with a mutant protein associated with Alzheimer's disease, in the presence of the agent; (b) measuring the amount of complex formation between the malate dehydrogenase protein and the mutant protein, following step (a); (c) contacting the malate dehydrogenase protein with the mutant protein in the absence of the agent; and (d) measuring the amount of complex formation between the malate dehydrogenase protein and the mutant protein, following step (c), whereby, if the amount of step (b) is less than the amount of step (d), then the agent is capable of treating Alzheimer's disease.
  • the mutant protein is amyloid beta peptide (ABETA).
  • the mutant protein is any other mutant protein known to be associated with Alzheimer's disease.
  • the present invention provides a method of identifying an agent capable of treating Huntington disease, the method comprising the steps of: (a) contacting a malate dehydrogenase protein with a mutant protein associated with Huntington disease, in the presence of the agent; (b) measuring the amount of complex formation between the malate dehydrogenase protein and the mutant protein, following step (a); (c) contacting the malate dehydrogenase protein with the mutant protein in the absence of the agent; and (d) measuring the amount of complex formation between the malate dehydrogenase protein and the mutant protein, following step (c), whereby, if the amount of step (b) is less than the amount of step (d), then the agent is capable of treating Huntington disease.
  • the mutant protein is Huntingtin. In another embodiment, the mutant protein is another protein known to contain poly-glutamine repeats. In another embodiment, the mutant protein is any other mutant protein known to be associated with Huntington disease. Each possibility represents a separate embodiment of the present invention.
  • the present invention provides a method of identifying an agent capable of treating Kennedy disease (also known as spinal and bulbar muscular atrophy, the method comprising the steps of: (a) contacting a malate dehydrogenase protein with a mutant protein, wherein the mutant protein is associated with Kennedy disease, in the presence of the agent; (b) measuring the amount of complex formation between the malate dehydrogenase protein and the mutant protein, following step (a); (c) contacting the malate dehydrogenase protein with the mutant protein in the absence of the agent; and (d) measuring the amount of complex formation between the malate dehydrogenase protein and the mutant protein, following step (c), whereby, if the amount of step (b) is less than the amount of step (d), then the agent is capable of treating Kennedy disease.
  • Kennedy disease also known as spinal and bulbar muscular atrophy
  • the mutant protein is androgen receptor. In another embodiment, the mutant protein is another protein known to contain poly-glutamine repeats. In another embodiment, the mutant protein is any other mutant protein known to be associated with Kennedy disease. Each possibility represents a separate embodiment of the present invention.
  • the present invention provides a method of identifying an agent capable of treating a neurodegenerative disorder, the method comprising the steps of: (a) contacting a malate dehydrogenase protein with a mutant microtubule- associated protein tau, wherein the mutant tau protein is associated with the neurodegenerative disorder, in the presence of the agent; (b) measuring the amount of complex formation between the malate dehydrogenase protein and the mutant tau protein, following step (a); (c) contacting the malate dehydrogenase protein with the mutant tau protein in the absence of the agent; and (d) measuring the amount of complex formation between the malate dehydrogenase protein and the mutant tau protein, following step (c), whereby, if the amount of step (b) is less than the amount of step (d), then the agent is capable of treating the neurodegenerative disorder.
  • the neurodegenerative disorder is Alzheimer's disease.
  • the neurodegenerative disorder is Pick's disease (PID).
  • the neurodegenerative disorder is progressive supranuclear palsy (PSP).
  • the neurodegenerative disorder is corticobasal degeneration (CBD).
  • the neurodegenerative disorder is frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP- 17).
  • the neurodegenerative disorder is any other neurodegenerative disorder linked to a mutant tau protein.
  • a complex of the present invention is fluorescently labeled.
  • the step of measuring an amount of a malate dehydrogenase-mutant SODl complex is performed by measuring a signal from the complex.
  • the signal is fluorescence signal.
  • the signal is a FRET signal.
  • an alteration in the signal is measured following addition of the test agent.
  • the signal is generated using FRET.
  • the signal is any other type of signal known in the art that can be engineered to be dependent on an intact malate dehydrogenase-mutant SODl complex.
  • the present invention provides methods readily generalizable by one skilled in the art to any type of quantitative or semi-quantitative signal that can be engineered to be dependent on an intact malate dehydrogenase-mutant SODl complex.
  • Each possibility represents a separate embodiment of the present invention.
  • Embodiments of the present invention provide agents and method of using same for treating neurodegenerative disorders, such as ALS.
  • the agents are peptide agents such as peptides or small molecules which can interfere with binding of cytoplasmic malate dehydrogenase to ALS-related SODl or abrogating the inhibition of the malate-aspartate shuttle in the neurons.
  • Additional embodiments of the present invention provide novel methods of screening for agents capable of interfering with binding of cytoplasmic malate dehydrogenase to SODl.
  • peptide encompasses native peptides (either degradation products, synthetically synthesized peptides or recombinant peptides) and peptidomimetics (typically, synthetically synthesized peptides), as well as peptoids and semipeptoids which are peptide analogs, which may have, for example, modifications rendering the peptides more stable while in a body or more capable of penetrating into cells.
  • Methods for preparing peptidomimetic compounds are well known in the art and are specified, for example, in Quantitative Drug Design, CA. Ramsden Gd., Chapter 17.2, F. Choplin Pergamon Press (1992), which is incorporated by reference as if fully set forth herein.
  • Natural aromatic amino acids, Trp, Tyr and Phe may be substituted by synthetic non-natural acid such as TIC, naphthylalanine (NoI), ring-methylated derivatives of Phe, halogenated derivatives of Phe or o-methyl-Tyr.
  • synthetic non-natural acid such as TIC, naphthylalanine (NoI), ring-methylated derivatives of Phe, halogenated derivatives of Phe or o-methyl-Tyr.
  • the peptides of the present invention may also include one or more modified amino acids or one or more non-amino acid monomers (e.g. fatty acids, complex carbohydrates etc).
  • amino acid or “amino acids” is understood to include the 20 naturally occurring amino acids; those amino acids often modified post-translationally in vivo, including, for example, hydroxyproline, phosphoserine and phosphothreonine; and other unusual amino acids including, but not limited to, 2- aminoadipic acid, hydroxylysine, isodesmosine, nor-valine, nor-leucine and ornithine.
  • amino acid includes both D- and L-amino acids.
  • Tables 1 and 2 below list naturally occurring amino acids (Table 1) and non- conventional or modified amino acids (Table 2) which can be used with the present invention.
  • the peptides of the present invention are preferably utilized in a linear form, although it will be appreciated that in cases where cyclization does not severely interfere with peptide characteristics, cyclic forms of the peptide can also be utilized.
  • the peptides of the present invention may be synthesized by any techniques that are known to those skilled in the art of peptide synthesis. For solid phase peptide synthesis, a summary of the many techniques may be found in J. M. Stewart and J. D. Young, Solid Phase Peptide Synthesis, W. H. Freeman Co. (San Francisco), 1963 and J. Meienhofer, Hormonal Proteins and Peptides, vol. 2, p. 46, Academic Press (New York), 1973. For classical solution synthesis see G. Schroder and K. Lupke, The Peptides, vol. 1, Academic Press (New York), 1965.
  • these methods comprise the sequential addition of one or more amino acids or suitably protected amino acids to a growing peptide chain.
  • amino acids or suitably protected amino acids Normally, either the amino or carboxyl group of the first amino acid is protected by a suitable protecting group.
  • the protected or derivatized amino acid can then either be attached to an inert solid support or utilized in solution by adding the next amino acid in the sequence having the complimentary (amino or carboxyl) group suitably protected, under conditions suitable for forming the amide linkage.
  • the protecting group is then removed from this newly added amino acid residue and the next amino acid (suitably protected) is then added, and so forth. After all the desired amino acids have been linked in the proper sequence, any remaining protecting groups (and any solid support) are removed sequentially or concurrently, to afford the final peptide compound.
  • a preferred method of preparing the peptide compounds of the present invention involves solid phase peptide synthesis.
  • the peptides of the present invention may be delivered to the subject using gene therapy techniques or as peptide molecules. It will be appreciated that since the agents of the present invention are peptides they are susceptible to break-down by the enzymes in the stomach. In order to improve drug delivery therefore, the peptide agents of the present invention may be combined with a mucoadhesive agent.
  • mucoadhesive agents e.g., mucoadhesive polymers are known which are believed to bind to the mucus layers coating the stomach and other regions of the gastrointestinal tract. Examples of mucoadhesive polymers as discussed herein include, but are not limited to chitosan, polyacrylic acid, hydroxypropyl methylcellulose and hyaluronic acid.
  • the mucoadhesive polymer is chitosan [Guggi et al., (2003) J of Controlled Release 92:125-135]. It will further be appreciated that delivery of peptide agents to the brain is restricted by the blood brain barrier. Over the years, several strategies to circumvent the blood brain barrier have been proposed, such as by transient osmotic opening of the BBB, high dosing (e.g., of chemotherapy), use of carrier systems such as antibodies, or even biodegradable implants. All these systems are contemplated by the present invention.
  • Liposomes are small vesicles (usually submicron sized) comprised of one or more concentric bilayers of phospholipids separated by aqueous compartments. It has been suggested that the use of an external ligand such as mannose can improve a liposomal particle's ability to cross the BBB [Huitinga et al, J exp Med 172 (1990) 1025-33; Umezawa F., Biochem Biophys Res Commun 153 (1988) 1038-44].
  • the mannosylated liposomes were shown to be incorporated in glial cells as opposed to neuronal cells, the former having a receptor for mannose [Umezawa F., Biochem Biophys Res Commun 153, 1988, 1038-44].
  • PCT Application, Publication No. WO9402178A1 to Micklus discusses the coupling of liposomes to an antibody binding fragment which binds to a receptor molecule present on the vascular endothelial cells of the mammalian blood-brain barrier.
  • the peptides perhaps may also be delivered by phages, or in a liquid or solid formulation, intranasally for example.
  • the peptides or small molecules of the present invention may be used to treat neurodegenerative disorders.
  • neurodegenerative disorders include, but are not limited to Amyotrophic lateral sclerosis (ALS), Alzheimer's Dementia, Alexander disease, Alper's disease, Ataxia telangiectasia, Batten disease, Bovine spongiform encephalopathy (BSE), Canavan disease, Cockayne syndrome, Corticobasal degeneration, Creutzfeldt-Jakob disease, Huntington disease, HIV- associated dementia, Kennedy's disease, Krabbe disease, Lewy body dementia, Machado- Joseph disease (Spinocerebellar ataxia type 3), Multiple sclerosis, Multiple System Atrophy, Neuroborreliosis, Parkinson disease, Pelizaeus-Merzbacher Disease, Pick's disease, Primary lateral sclerosis, Prion diseases, Refsum's disease, Sandhoff disease, Schilder's disease, Schizophrenia, Spielmeyer-Vogt-Sjogren-Batten disease, Spinocerebellar ataxia and Spinal muscular atrophy.
  • the peptides or small molecule agents of the present invention may be delivered to the subject per se or as part of a pharmaceutical composition.
  • a "pharmaceutical composition” refers to a preparation of one or more of the active ingredients described herein with other chemical components such as physiologically suitable carriers and excipients.
  • the purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.
  • active ingredient refers to the DJ-I peptides of the present invention accountable for the biological effect.
  • physiologically acceptable carrier refers to the phrases “physiologically acceptable carrier”.
  • pharmaceutically acceptable carrier refers to a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.
  • An adjuvant is included under these phrases.
  • excipient refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient. Examples, without limitation, of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.
  • compositions of the present invention may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
  • compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active ingredients into preparations which, can be used pharmaceutically.
  • the active ingredients of the pharmaceutical composition may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological salt buffer.
  • excipient refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient.
  • excipients examples include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols. Techniques for formulation and administration of drugs may be found in "Remington's Pharmaceutical Sciences,” Mack Publishing Co., Easton, PA, latest edition, which is incorporated herein by reference.
  • Suitable routes of administration may, for example, include oral, rectal, transmucosal, especially transnasal, intestinal or parenteral delivery, including intramuscular, subcutaneous and intramedullary injections as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections.
  • compositions of the present invention may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
  • compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active ingredients into preparations which, can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
  • the active ingredients of the pharmaceutical composition may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological salt buffer.
  • physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological salt buffer.
  • penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
  • compositions described herein may be formulated for parenteral administration, e.g., by bolus injection or continuous infusion.
  • Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multidose containers with optionally, an added preservative.
  • the compositions may be suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • Pharmaceutical compositions for parenteral administration include aqueous solutions of the active preparation in water-soluble form. Additionally, suspensions of the active ingredients may be prepared as appropriate oily or water based injection suspensions.
  • Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acids esters such as ethyl oleate, triglycerides or liposomes.
  • Aqueous injection suspensions may contain substances, which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol or dextran.
  • the suspension may also contain suitable stabilizers or agents which increase the solubility of the active ingredients to allow for the preparation of highly concentrated solutions.
  • the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water based solution, before use.
  • a suitable vehicle e.g., sterile, pyrogen-free water based solution
  • compositions suitable for use in context of the present invention include compositions wherein the active ingredients are contained in an amount effective to achieve the intended purpose. More specifically, a therapeutically effective amount means an amount of active ingredients effective to prevent, alleviate or ameliorate symptoms of a disorder (e.g., neurodegenerative disorder) or prolong the survival of the subject being treated.
  • a disorder e.g., neurodegenerative disorder
  • the therapeutically effective amount or dose can be estimated from animal models to achieve a desired concentration or titer. Such information can be used to more accurately determine useful doses in humans.
  • Toxicity and therapeutic efficacy of the active ingredients described herein can be determined by standard pharmaceutical procedures in experimental animals.
  • the data obtained from these animal studies can be used in formulating a range of dosage for use in human.
  • the dosage may vary depending upon the dosage form employed and the route of administration utilized.
  • the exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g., Fingl, et al., 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 p.l).
  • Dosage amount and interval may be adjusted individually to provide cell numbers sufficient to induce normoglycemia (minimal effective concentration, MEC).
  • MEC minimum effective concentration
  • the MEC will vary for each preparation, but can be estimated from in vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. Detection assays can be used to determine plasma concentrations.
  • compositions to be administered will, of course, be dependent on the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician, etc.
  • compositions of the present invention may, if desired, be presented in a pack or dispenser device, such as an FDA-approved kit, which may contain one or more unit dosage forms containing the active ingredient.
  • the pack may, for example, comprise metal or plastic foil, such as a blister pack.
  • the pack or dispenser device may be accompanied by instructions for administration.
  • the pack or dispenser may also be accommodated by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or human or veterinary administration. Such notice, for example, may be of labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert.
  • Compositions comprising a preparation of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition, as if further detailed above.
  • DMEM Dulbecco's modification of Earle's medium
  • FCS heat-inactivated fetal calf serum
  • L-glutamine L-glutamine
  • penicillin streptomycin EZ- First Strand cDNA Synthesis RNA kit
  • L-glutamine G418 and antibiotics were obtained from Biological Industries (Beit Haemek, Israel); Doxycyclin, thiazol blue (MTT), alcohol dehydrogenase, PES, Hygromycin B NADH and NAD from Sigma (Sigma-Aldrich, St. Louis, MO); Lipofectamin 2000 from Invitrogen (San Diego, CA); (rabbit) anti- human SODl antibodies from Santa Cruz, Inc.
  • NSC-34 cells were provided by Dr. Neil Cashman.
  • pcDNA3.1 plasmids containing wild-type or G93A-mutant hSODl cDNA were provided by Dr. David Gozal.
  • NSC- 34 cell lines stably expressing an inducible form of WT-hSODl or G93A-hSODl fused with GFP at the C-terminal end were obtained by cotransfection with pUHD 172-1 and pTRE2hyg-WT-hSODl-GFP or pTRE2hyg-G93A-hSODl-GFP cDNA.
  • CCTAGCGGCCGCAAGCAGTGGTATCAACGCAGAGT-S' (SEQ ID NO: 3) that included a Notl restriction site.
  • the cDNA was digested with Notl and subjected to ligation with a set of 3 vectors pQBI25 fc 1,2,3 that contains the blue fluorescence protein (BFP) encoding sequence. Ligation products were electroporated into DH5 ⁇ bacteria, to obtain l*10 A 6 clones.
  • pQBI -BFP-GFP plasmid A plasmid containing a BFP-GFP chimera was prepared in order to serve as a positive control for the FRET studies.
  • pQBI25 plasmid was digested with CIaI and Notl.
  • pEGFP plasmid was used to obtain GFP DNA by PCR amplification using the following primers: Forward 5'- CTCAGATATCGATCTCAAGCTO 1 (SEQ ID NO: 6) Reverse 5'- CCTCTACAAATGTGGTATGGCTG-3' (SEQ ID NO: 7).
  • the GFP DNA was digested with CIaI and Notl and subjected to ligation with the pQBI25 plasmid with a 23 amino acid linker.
  • FRET Live Cell Screening The mouse cDNA library, the pQBI -BFP-GFP and pQBI plasmids were transfected into the WT-hSODl-GFP and G93A-hSODl-
  • GFP cells using lipofectamine transfection reagent. After 24h, lug/ml doxycycline was added to induce expression of the hSODl-GFP chimera. 24h later, cells were washed with PBS harvested and analyzed by fluorescence activated cell sorting (FACS) using an excitation UV laser set at 0.133 W and a 530/30 nm emission filter. pQBI -BFP-GFP transfected NSC-34 cells and pQBI -BFP-GFP transfected WT-hSODl-GFP and G93A-hSODl-GFP cells were used to identify cells with positive FRET signal.
  • FACS fluorescence activated cell sorting
  • pQBI25 which contains the BFP
  • WT-hSODl- GFP and G93A-hSODl-GFP were used to evaluate FRET signals coming from interactions between the BFP and GFP moieties.
  • the gating area was set on the population defined by a positive FRET signal.
  • the WT-hSODl-GFP and G93A hSODl-GFP cells transfected with the mouse spinal cord and motor cortex library were subjected to FACS to sort out cells showing a positive FRET signal.
  • Frame 1 Sense 5 1 -AATTCTGCGATATCGCGGCCGCG-3 l (SEQ ID NO: 10); Anti sense 5'-GATCCGCGGCCGCGATATCGCA-S' (SEQ ID NO: 11); Frame 2 sense 5'-AATTCTGCCGATATCGCGGCCGCG-S' (SEQ ID NO: 12); anti sense 5'-GATCCGCGGCCGCGATATCGGCA-3 I (SEQ ID NO: 13);
  • Frame 3 sense 5'-AATTCTGCCCGATACGCGGCCGCG-S' (SEQ ID NO: 14); anti sense 5 1 -GATCCGCGGCCGCGATATCGGGCA-3 l (SEQ ID NO: 15).
  • NSC-34 cells were cotransfected with pCDNA3.1-WT-hSODl and pEYFP-cytMDH or with pCDNA3.1-G93A-hSODl and pEYFP-cytMDH. After 48 hours cells were lysed in solubilization buffer (5OmM Hepes PH7.5, 150 mM NaCl, 10% glycerol, 1% Triton -X, 1 mM EDTA, 1 Mm EGTA and 1.5 mM MgCl 2 ). Samples containing 0.5 mg protein were subjected to immunoprecipitation using anti hSODl antibodies immobilized on protein A-coupled sepharose beads.
  • solubilization buffer 5OmM Hepes PH7.5, 150 mM NaCl, 10% glycerol, 1% Triton -X, 1 mM EDTA, 1 Mm EGTA and 1.5 mM MgCl 2 .
  • Cells were solubilized in 5OmM Hepes buffer pH-7.5 containing 15OmM NaCl, 10% glycerol, 1% Triton X-100, ImM EDTA, ImM EGTA and 1.5mM MgC12).
  • Cell lysates were diluted with sodium dodecyl sulfate (SDS) loading buffer. The mixture was boiled for 3 min and stored at -80°C for subsequent analysis. Proteins (100 ⁇ g per lane) were subjected to 7.5% (v/v) SDS-polyacrylamide gel electrophoresis and the resolved proteins were electroblotted onto nitrocellulose membranes.
  • SDS sodium dodecyl sulfate
  • Nonspecific binding sites on the nitrocellulose membranes were blocked by incubation for 1 h with 5% (w/v) non-fat milk in Tris-buffered saline (TBST), containing 150 mM NaCl, 1O mM Tris-HCl, pH 7.4, and 0.1% (v/v) Tween-20.
  • TST Tris-buffered saline
  • the nitrocellulose membranes were incubated overnight at 4°C with primary antibodies (anti human SODl; anti- GFP; anti- ⁇ -actin) diluted 1 :1000 in TBST with 1% (w/v) bovine serum albumin.
  • nitrocellulose membranes were incubated for 1 h at room temperature (20°C) with IRDey-800-linked secondary antibodies, diluted 1 : 10,000 in TBST, washed in TBST and subjected to analysis on the odyssey fluorescence reader from Li-Cor bioscience.
  • the supernatants (containing the cytosol and mitochondria) were collected and centrifuged at 10,000 rpm for 15min. Supernatants (cytosol) and pellets (mitochondria) were collected. The pellets were suspended in 250ul of 1OmM Tris-HCl buffer pH-7.4 containing 25OmM sucrose, and 2mM EDTA containing 0.5% Tween.
  • NAD + and NADH concentrations were measured by spectrophotometric enzymatic cycling assay as described (15).
  • the screening method was based on the fluorescence resonance energy transfer (FRET) system between cyan fluorescence protein (CFP) chimera proteins and yellow fluorescence protein (YFP) chimera proteins.
  • FRET fluorescence resonance energy transfer
  • CFP cyan fluorescence protein
  • YFP yellow fluorescence protein
  • the present inventors designed and used this system to identify the specific interaction of G93A SODl with MDHl so as to identify a motif within MDHl that is critical for the G93A SODl - MDHl interaction.
  • the agents tested were peptides derived from MDHl.
  • a Myc-tagged peptide library expressing small fragments of the MDHl was prepared.
  • MDHl cDNA was digested with AIuI or/and Dpnl and the fragments were cloned so that each peptide was placed in the correct reading frame of the original protein and in frame to the human myc tag sequence.
  • G93A SODl-CFP and MDHl- YFP expression plasmids were transfected into NSC-34 cells with and without the myc-tagged library.
  • the DNA sequence from the sorted cells was re-cloned. Four clones were obtained, one corresponding to amino acids 14-27 of the cytMDH protein GQIAHSLLYSIGNG (SEQ ID NO: 2) and three corresponding to amino acids 217- 239 of the cytMDH protein SWLKGEFITTVQQRGAAVIKARK (SEQ ID NO: 1). The identified clones were re-analyzed in the FACS-based system to verify their ability to compete for the G93A SODl - MDHl interaction at 1:1 :1 ratio levels.
  • NSC-34 cells were transfected with equal amounts of G93A-hSODl-CFP and cytMDH- YFP and the suspected myc-tagged cytMDH peptide-expressing plasmids.
  • Peptides that prevented the FRET namely those that shifted the cell population toward the FRET negative gating area, were considered to impair the G93A-hSODl- CFP /cytMDH- YFP interaction.
  • the identified myc-tagged peptide was sequenced and identified as amino acids 217-239 of the cytMDH protein SWLKGEFITTVQQRGAAVIKARK (SEQ ID NO: 1).
  • the functional significance of the loss of such interaction was assessed by alleviation of the rotenone (a mitochondrial inhibitor) or low-glucose challenge in NSC-34 clones expressing an inducible form of the mutant G93A SODl-GFP as monitored by cell survival.
  • the SWLKGEFITTVQQRGAAVIKARK (SEQ ID NO: 1) peptide was synthesized (SBS Gentech Beijing) with 5,6-TAMRA modification (to allow detection) at the N-terminus.
  • the TAMRA-modified peptide was dissolved in 10% acetic acid and added to cell culture medium in culture medium containing 1% ethanol.
  • 15,000 cells (WT-hSODl or G93A-hSODl) were seeded in each well of a 96 well-plate in DMEM, 10% serum. 24 hours later, the cells were incubated with 3mM octanoic acid with and without 1-10 micromole/L rotenone in DMEM, 10% serum for 24 hours. Or, cells were incubated with 3mM octanoic acid and medium replaced with regular (5 mg/L) or low (1 mg/ml) glucose in DMEM with 5% serum for 72 hours.
  • G93A SODl-GFP is due to inhibition of the malate-aspartate shuttle, octanoic acid will provide an alternative energy source through the alternative shunt and the survival of the cells upon rotenone or low-glucose challenge will improve.
  • EXAMPLE 1 FRET analysis reveals G93A-hSODl interaction with cytMDH
  • NSC-34 motor neuron-derived cell lines
  • FRET acceptors A cDNA chimera library was generated from mouse spinal and cortical motor neurons wherein the clones were fused with BFP at the N-terminal end, to be used as FRET donors.
  • FACS cell sorter
  • emission of the acceptor (GFP) during donor (BFP) excitation should indicate a positive FRET signal and thus be interpreted as evidence of proximity of the donor- and acceptor-tagged proteins.
  • GFP acceptor
  • BFP donor
  • a BFP-GFP chimera was first constructed to serve as a positive control for the FRET signal and set the FACS gating area on the population defined by a positive FRET signal.
  • Figure 1 depicts FACS analysis of the BFP-GFP chimera and BFP expression plasmids transfected into the G93A-hSODl-GFP ( Figure IA) and the parent NSC-34 ( Figure IB) cell line.
  • FACS analysis of the G93A-hSODl- GFP cells transfected with the GFP-BFP chimera reveals two distinct cell populations (Rl and R2). Only one of these populations (R2) is present in the parent NSC-34 cells transfected with the BFP-GFP chimera in the absence of the GFP-tagged hSODl, thus identifying Rl as contaminating (non-FRET) fluorescence from the GFP-tagged h- SODl protein.
  • FIG. 1C FACS analysis of the G93A-hSODl-GFP cells transfected with BFP ( Figure 1C) revealed a single population of cells (Rl) that corresponded to the non- FRET fluorescence of the GFP fluorophore and no contaminating BFP emission.
  • R2 was thus defined as a positive FRET population.
  • This FRET-positive cell population is thus only generated when proteins from the BFP-tagged library are in close proximity with G93A-hSODl-GFP or WT-hSODl-GFP.
  • the FACS gating area was thus set on the R2 population to sort out cells in which there is an apparent association between the hSODl-GFP derivatives and a BFP-tagged candidate protein from the mouse motor-cortex spinal cord library.
  • G93A-hSODl-GFP and WT-hSODl-GFP NSC-34 cells were transfected with the BFP-tagged library and induced to express the hSODl proteins. Single cells demonstrating a positive FRET signal were sorted out using FACS. The initial screening identified a number of FRET positive, candidate BFP-tagged proteins that appeared to differentially interact with G93A-hSODl-GFP but not WT-hSODl-GFP. The most frequently occurring ones were HSP-70, which has already been shown to interact with hSODl (16), myelin, aldolase-la, transferrin, the 3' end of kinesin-5a and cytosolic malate dehydrogenase (cytMDH).
  • NSC-34 cells were transfected transiently with either G93A-hSODl or WT-hSODl fused to CFP expression plasmids and/or expression plasmids encoding YFP fused to candidate interacting proteins, and the interaction was assessed 48 hours later by FRET confocal microscopy.
  • FRET was measured as enhanced emission of the acceptor (YFP) during donor (CFP) excitation.
  • YFP emission was contaminated by both direct excitation of YFP and by CFP emission in the YFP range.
  • FRET efficiency was quantified using spectrum measurements as described (14).
  • Emission spectra were obtained upon excitation of the donor at 405 nm of cells expressing G93A-hSODl- CFP and YFP-tagged candidate protein (Fig. 2A, data set A).
  • the FRET-related YFP emission (F405) was extracted by subtracting the CFP spectrum collected from control cells expressing the G93A-hSODl-CFP alone (Fig. 2A, data set B).
  • the YFP spectrum upon direct excitation of the acceptor (F514) was also measured.
  • the (F405/F514) ratio of the emission spectra obtained upon excitation at 405nm and 514nm of cells expressing G93A-hSODl-CFP and YFP-tagged candidate protein was calculated (RatioA; Fig 2B).
  • RatioAO ratio of the emission spectra obtained upon excitation at 405nm and 514nm of cells expressing only the YFP- tagged protein was calculated (RatioAO; Fig 2B). Because RatioA is not dependent on wavelength, it was used to check for significant contaminations by other fluorescence sources (14). The difference (RatioA - RatioAO), that is directly proportional to FRET efficiency, was evaluated as an indicator of proximity. Similar measurements were performed for cells expressing WT-hSODl-CFP and YFP-tagged candidate protein (Fig. 2C, data set A) and WT-hSODl-CFP alone (Fig. 2C, data set B).
  • cytMDH- YFP were expressed. cytMDH- YFP was co-immunoprecipitated with G93A-hSODl but not with WT-hSODl, thus further confirming the cytMDH- YFP-G93A-hSODl interaction.
  • the YFP-tagged cytMDH retained normal function. This was shown by measurement of MDH activity in naive NSC-34 cells transfected with cytMDH- YFP
  • EXAMPLE 4 G93A-hSODl upregulates cytMDH but decreases in vivo cytMDH activity
  • endogenous cytMDH enzymatic activity was assessed in vitro in lysates from cells of the lines stably containing the inducible G93A-hSODl-GFP and
  • WT-hSODl-GFP with and without doxycycline treatment.
  • the rate of conversion of oxaloacetate to malate in lysates of G93A-hSODl-GFP cells was only slightly (10%) increased compared to non-induced cells.
  • the respective cytMDH activity in non- induced WT-hSODl-GFP cells was comparable to non-induced G93A-hSODl-GFP cells and did not change after induction of WT-hSODl expression (Fig 5).
  • WT-hSODl-GFP expressing cells WT-hSODl-GFP expressing cells.
  • G93A- hSODl-GFP cells had higher lactate and lower malate values compared to the cells expressing the WT-hSODl-GFP cells.
  • NADH/NAD + ratio in the cytosol and mitochondria was assessed in both cell lines with and without hSODl induction (Fig. 7). There were no significant differences in NADH/NAD + in the cytosol between the non-induced G93A-hSODl-GFP and WT- hSODl-GFP cells. NADH/NAD + ratio in the cytosol did not differ in induced compared to non-induced G93A-hSODl-GFP as well as WT-hSODl-GFP cells.
  • NADH/NAD + ratio was significantly higher in the non-induced G93A-hSODl-GFP than in the WT-hSODl-GFP cells.
  • a significant elevation in the mitochondrial NADH/NAD "1" ratio was found after a 48 hour- induction of expression of G93A-hSODl-GFP but not of WT-hSODl-GFP.
  • EXAMPLE 5 Identification of peptide agents that inhibit the formation of the complex between MDHl and mutant G93A-hSODl
  • SWLKGEFITTVQQRGAAVIKARK (SEQ ID NO: 1), is located at the MDHl surface, close to the MDHl dimerization site ( Figure 8; peptide is highlighted in yellow, and monomeric units of MDHl are in blue and green. NADH is represented in stick-and-ball model).
  • Cells transfected with constructs encoding G93A-hSODl-CFP and YFP were utilized as the negative FRET control (A), while cells co-transfected with constructs encoding G93A-hSODl-CFP /cytMDH- YFP and myc-tagged 14-27 peptide (D), found not to inhibit the interaction between the two proteins at 1 :1 :1 stoichiometry, served as a control for non-specific effects of the myc tag.
  • SWLKGEFITTVQQRGAAVIKARK (SEQ ID NO: 1) peptide was synthesized (SBS Gentech Beijing) with 5,6-TAMRA modification (to allow detection) at the N-terminus, dissolved in 10% acetic acid, and diluted in cell culture medium containing 1% ethanol. Thus, 15,000 cells (WT-hSODl or G93A-hSODl) seeded in each well of 96 wells plate in DMEM, 10% serum and doxycline (to induce expression of the hSODl proteins).
  • EXAMPLE 7 Gain of toxic interaction of G93A SODl-GFP is due to inhibition of the malate-aspartate shuttle
  • the effects of octanoic acid on survival of rotenone- and low glucose challenged cells expressing WT-hSODl-GFP and G93A-hSODl-GFP were assessed ( Figure 11).
  • Treatment with rotenone (1.25 micromol/liter for 24h) reduced cell viability to a greater extent in G93A-hSODl-GFP than WT-hSODl-GFP expressing cells as measured by methylene blue assay (relative to the survival without rotenone).
  • an interaction was identified, using novel FRET techniques in live motor-neuron derived cells, between mutant hSODl-GFP (disease protein) and BFP-tagged cytMDH, which does not occur with the wild type hSODl-GFP. Furthermore, using confocal microscopy close proximity was demonstrated between these proteins using a different pair of fluorophores and transient transfection into the parent NSC-34 cell line. Further interaction was demonstrated between BFP-tagged cytMDH and untagged mutant hSODl, which does not occur with untagged WT- hSODl in the cells using pull-down immunoprecipitation techniques.
  • the tagged cytMDH retained MDH enzymatic activity, showing that its conformation was largely normal. Moreover, expression of the mutant protein affected expression of endogenous cytMDH (increase) and the levels of cell malate (decrease) and lactate (increase) as well as the NADH/NAD + ratio in the mitochondria (increase), all of which are compatible with the consequences of inhibition of endogenous cytMDH by G93A-hSODl and are not seen with the WT-hSODl .
  • Malate dehydrogenases (MDH, L-malate:NAD oxidoreductase, EC 1.1.1.37), catalyze the NAD/NADH-dependent interconversion of malate and oxaloacetate in the cytoplasm (cytMDH) and mitochondria (MitMDH).
  • cytMDH cytoplasm
  • MitMDH mitochondria
  • This reaction plays a key part in the malate/aspartate shuttle between the cytoplasm across the mitochondrial membrane, and in the tricarboxylic acid cycle within the mitochondrial matrix.
  • the association between the mutant hSODl with cytMDH may rely on structural properties of these proteins and imply that some structural properties of the mutant hSODl differ from those of the wild-type enzyme.
  • Cytosolic MDH is a key enzyme in the malate-aspartate shuttle which is considered the most important shuttle in the brain and is particularly important in neurons.
  • the malate-aspartate shuttle and the glycerol phosphate shuttle act to transfer reducing equivalents from NADH in the cytosol to the mitochondria, since the inner mitochondrial membrane is impermeable to NADH and NAD + (18).
  • cytMDH converts oxaloacetate to malate, at the same time reoxidizing NADH in the cytosol to NAD + .
  • Malate then enters the mitochondria in exchange for ⁇ -ketoglutarate.
  • Mitochondrial MDH which is part of the tricarboxylic acids (TCA) cycle enzyme, converts malate to oxaloacetate, at the same time reducing NAD + , forming equivalent amounts of NADH.
  • This transfer of reducing equivalents is essential for maintaining a favorable NAD + /NADH ratio required for the oxidative metabolism of glucose and synthesis of neurotransmitters in brain. Inhibition of this shuttle thus impairs the utilization of glucose, which is a main source of metabolic energy in the neurons favoring the anaerobic option (formation of lactate) over the aerobic option (TCA cycle) and resulting in a lower ATP yield.
  • ROS reactive oxygen species
  • the interaction between the mutant G93A-hSODl protein with cytMDH may result in inhibition of the malate-aspartate shuttle, leading to increased NADHTNAD + ratio in the mitochondria.
  • the latter results in inhibition of ⁇ -KGDH and elevates deleterious ROS production.
  • Increase in ROS may inhibit the activity of HIF-l ⁇ -prolyl-4-hydroxylases (PHD) which acts to enhance the degradation of hypoxia induced factor l ⁇ (23).
  • PHD HIF-l ⁇ -prolyl-4-hydroxylases
  • a decrease in the cytosolic PHD substrate ⁇ -Ketoglutarate might also lead to a decrease in PHD activity, resulting in an increase in HIF- l ⁇ .
  • HIF- l ⁇ induces PHD expression thereby promoting its own degradation (24).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention provides compositions for treating neurodegenerative diseases, including ALS, involving complex formation of cytosolic malate dehydrogenase with certain neurodegenerative disease-causing proteins, comprising an agent capable of reducing an interaction between a malate dehydrogenase protein and a conformationally altered or mutant protein associated with a neurodegenerative disorder, including mutant SOD1 protein. The present invention also provides methods of identifying an agent capable of treating such disorders, including ALS, comprising testing agents for the ability to disrupt or prevent formation of a malate dehydrogenase complex with a conformationally altered or mutant protein associated with a neurodegenerative disorder, including MDH-mutant-SOD1 complex, and methods of treating neurodegenerative disorders.

Description

CYTOPLASMIC MALATE DEHYDROGENASE (MDHl) TARGETED TREATMENT FOR NEURODEGENERATIVE DISEASES
FIELD OF THE INVENTION The present invention relates to agents including peptides and small molecules capable of preventing interactions between cytoplasmic malate dehydrogenase and disease causing proteins, useful in the treatment of neurodegenerative disorders and methods of screening thereof.
BACKGROUND Amyotrophic lateral sclerosis (ALS) is an adult-onset, fatal motor-neuron neurodegenerative disease. The molecular pathways leading to motor neuron injury and cell death in ALS are incompletely understood. In about 3% of ALS cases, the disease is caused by mutations in the gene encoding the human copper-zinc superoxide dismutase (hSODl) gene. More than 90 ALS-related mutations in the hSODl gene have been identified in familial ALS. These suggested toxic gain of function rather than loss of catalytic hSODl activity as the cause of ALS, but the nature of the toxicity has not been determined. Mitochondrial dysfunction and excessive production of reactive oxygen species (ROS) have repeatedly been demonstrated in cells expressing the mutant G93A-hSODl, an example of such mutations (1-4). These changes mirror alterations in mitochondrial electron transport chain (ETC) activities observed in ALS patients (3,5,6).
Malate dehydrogenases (MDH, L-malate:NAD oxidoreductase, IUBMB Enzyme Nomenclature EC 1.1.1.37) play an important role in mitochondrial respiration. Specifically, they catalyze the NAD/NADH-dependent interconversion of malate and oxaloacetate in the cytoplasm (cytMDH) and mitochondria (MitMDH). This reaction plays a key part in the malate/aspartate shuttle between the cytoplasm across the mitochondrial membrane, and in the tricarboxylic acid cycle within the mitochondrial matrix.
Previous studies have indicated normal or increased malate dehydrogenase (MDH) activity in other neurodegenerative disorders such as Alzheimer's Disease
(AD) [Butterworth and Besnard, Metab Brain Dis 1990:5; 179-184, Miulli et al. J
Am Osteopath Assoc 1993:93; 670-676, den Velde and Stam, J Am Geriatr Soc 1976:24; 12-16, Sheu et al. Ann Neurol 1985:17; 444-449]. Korolainen et al. [Neurobiol Aging. 2006:27;42-53] discloses increased amounts of mitochondrial glutamate dehydrogenase and cytosolic malate dehydrogenase in AD brains. Furthermore, Korolainen teach that these two enzymes exhibit a significantly decreased degree of oxidation in AD brains compared to controls. [Korolainen et al. Neurobiol Aging. 2006:27;42-53].
A role of MDH in neurodegenerative disease etiology has not been described until now. Rather, changes in MDH activity were considered to be the outcome and not the cause of neurodegeneration. For example, Ferraiuolo et al [Journal of Neuroscience, 2007, 27(34):9201-9219] teaches that amongst the myriad of up- regulated genes, malate dehydrogenase is also upregulated during ALS as detected by microarray analysis. None of the above references disclose or suggest the presence of a MDH complex with a neurodegenerative disease-causing protein or its utility as a therapeutic target for ALS or any neurodegenerative diseases. SUMMARY OF THE INVENTION
The present invention provides compositions and methods of treating ALS and neurodegenerative disorders in a subject, comprising an agent .capable of reducing or inhibiting an interaction between a malate dehydrogenase (MDH) protein and a neurodegenerative disease causing protein such as an SODl mutant protein. The present invention also provides methods of identifying an agent capable of treating ALS, comprising testing candidate agents for the ability to disrupt or prevent formation of a malate dehydrogenase complex with a conformationally altered or mutant neurodegenerative disease-causing protein.
The present invention is based in part on the unexpected finding that a cytoplasmic enzyme, malate dehydrogenase, forms a complex with specific mutant proteins associated with neurodegenerative processes. The present invention is exemplified by specific MDHl -derived peptides comprising the interacting motif that compete with MDHl for the interaction site.
In one aspect, the present invention provides a method of treating ALS in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an agent capable of reducing an interaction between malate dehydrogenase and an SODl protein, thereby treating ALS. In one embodiment, the target SODl protein is a mutant SODl protein. In another embodiment, the mutant SODl protein is associated with amyotrophic lateral sclerosis (ALS). In another embodiment, the agent is a peptide. In a specific embodiment, the agent is a peptide derived from the sequence of a MDH protein. Each possibility represents a separate embodiment of the present invention.
In another aspect, the present invention provides a method of treating a neurodegenerative disorder, the method comprising administering to an individual in need thereof a therapeutically effective amount of an agent capable of increasing brain mitochondrial respiration, thereby treating the neurodegenerative disorder, with the proviso that said agent is not pyruate or oxaloacetate. In one embodiment, the agent is capable of increasing cytoplasmic malate dehydrogenase activity in a subject in need thereof. In another embodiment, the agent is capable of increasing cytoplasmic malate levels in a subject in need thereof. In another embodiment, the agent is a peptide agent. In another embodiment, the peptide agent comprises at least 4-7 consecutive amino acids of human malate dehydrogenase. In another embodiment the peptide agent comprises at least 8-18 contiguous amino acids of human malate dehydrogenase. In another embodiment, the agent comprises the sequence set forth in SEQ ID NO: 1, corresponding to amino acids 217-239 of the cytMDH protein SWLKGEFITTVQQRGAAVIKARK (SEQ ID NO: 1). Each possibility represents a separate embodiment of the present invention.
The agent of methods and compositions of the present invention is, in certain embodiments, a peptide. In some embodiments, the peptide comprises a fragment of a malate dehydrogenase protein. In another embodiment, the malate dehydrogenase protein is a cytosolic malate dehydrogenase protein (cytMDH). In another embodiment, the malate dehydrogenase protein is a cytMDH malate dehydrogenase protein isoform. In another embodiment, the malate dehydrogenase protein is a human malate dehydrogenase protein. In another embodiment, the malate dehydrogenase protein is a human cytMDH protein isoform. In another embodiment, the malate dehydrogenase is any other malate dehydrogenase known in the art. Each possibility represents a separate embodiment of the present invention.
In another embodiment, the present invention provides a fragment of G93A- hSODl of 19-50 amino acids in length, the peptide comprising the sequence set forth in SEQ ID NO: 1. In another embodiment, the G93A-hSODl fragment is 19-45 amino acids in length. In another embodiment, the G93A-hSODl fragment is 19-40 amino acids in length. In another embodiment, the G93A-hSODl fragment is 19-35 amino acids in length. In another embodiment, the G93A-hSODl fragment is 19-30 amino acids in length. In another embodiment, the G93A-hSODl fragment is 19-25 amino acids in length. In another embodiment, the G93A-hSODl fragment is 25-45 amino acids in length. In another embodiment, the G93A-hSODl fragment is 25-40 amino acids in length. In another embodiment, the G93A-hSODl fragment is 25-35 amino acids in length. In another embodiment, the G93A-hSODl fragment is 25-30 amino acids in length. In another embodiment, a peptide of the present invention has the sequence set forth in SEQ ID NO: 1. Each possibility represents a separate embodiment of the present invention.
In another embodiment, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and as an active ingredient, a peptide agent capable of preventing an interaction between malate dehydrogenase and a mutant SODl protein, wherein said mutant SODl protein is associated with an amyotrophic lateral sclerosis (ALS).
In another embodiment, the present invention provides a method of identifying an agent capable of treating ALS, the method comprising the steps of (a) contacting said agent with a preparation of a complex of a malate dehydrogenase protein and a mutant SODl protein, wherein said mutant SODl protein is associated with amyotrophic lateral sclerosis (ALS); and measuring an amount of the complex in the presence of the agent, whereby, if said amount of the complex in the presence of the agent is less than the initial amount, then said agent is capable of treating amyotrophic lateral sclerosis. In another embodiment, the present invention provides a method of identifying an agent capable of treating ALS, the method comprising the steps of: (a) contacting a malate dehydrogenase protein with a mutant SODl protein, wherein the mutant SODl protein is associated with amyotrophic lateral sclerosis (ALS), in the presence of the agent; (b) measuring the amount of complex formation between the malate dehydrogenase protein and the mutant SODl protein, following step (a); c) contacting the malate dehydrogenase protein with the mutant SODl protein in the absence of the agent; and d) measuring the amount of complex formation between the malate dehydrogenase protein and the mutant SODl protein, following step (c), whereby, if the amount of step (b) is less than the amount of step (d), then the agent is capable of treating amyotrophic lateral sclerosis.
In another embodiment, a complex of the present invention is fluorescently labeled. In another embodiment, the step of measuring an amount of a malate dehydrogenase-mutant SODl complex is performed by measuring a signal from the complex. In another embodiment, the signal is fluorescence signal. In another embodiment, the signal is a FRET signal. In another embodiment, an alteration in the signal is measured following addition of the test agent. As described herein, the present invention provides methods readily generalizable by one skilled in the art to any type of quantitative or semi-quantitative signal that can be engineered depend on an intact malate dehydrogenase-mutant SODl complex. Each possibility represents a separate embodiment of the present invention.
BRIEF DESCRIPTION OF THE DRAWINGS
The invention is herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of the preferred embodiments of the present invention only, and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for a fundamental understanding of the invention, the description taken with the drawings making apparent to those skilled in the art how the several forms of the invention may be embodied in practice.
In the drawings: Figure 1. FACS analysis of A) G93A-hSODl-GFP expressing NSC-34 cells transfected with BFP-GFP chimera expression plasmid; B) NSC-34 cells transfected with BFP-GFP chimera expression plasmid; and C) G93A-hSODl-GFP expressing NSC-34 cells transfected with BFP expression plasmid. Excitation-UV light; Emission- 530nm. Figure 2. A) Emission spectra obtained upon excitation at 405nm of cells expressing G93A-hSODl-CFP and YFP-tagged candidate protein (data set A). The FRET-related YFP emission (Fig. 2A- F405) was extracted by subtracting the CFP spectrum collected from control cells expressing the G93A-hSODl-CFP alone (data set B). B) F405/F514 (Ratio A) in cells expressing G93A-hSODl-CFP and YFP- tagged candidate and F405/F514 caused by the direct excitation of YFP (Ratio AO) in NSC-34 cells expressing only the YFP-tagged candidate protein. C) Emission spectra obtained upon excitation at 405 nm of cells expressing WT-hSODl-CFP and YFP- tagged candidate protein (Fig. 2C, data set A). The FRET-related YFP emission (Fig. 2C-F405) was extracted by subtracting the CFP spectrum collected from control cells expressing the G93A-hSODl-CFP alone (Fig. 2C, data set B). B) F405/F514 (Ratio A) in cells expressing WT-hSODl-CFP and YFP-tagged candidate and F405/F514 caused by the direct excitation of YFP (Ratio AO) in NSC-34 cells expressing only the YFP-tagged candidate protein.
Figure 3. Co-immunoprecipitation of cytMDH with hSODl. NSC-34 cells were co-transfected with YFP-cytMDH and untagged WT-hSODl or untagged G93A-hSODl solubilized 48h later and subjected to immunoprecipitation with anti- hSODl antibodies. A) Western blot of YFP-cytMDH and actin in samples pre- immunoprecipitation. B) Western blot of YFP-cytMDH and hSODl derivatives in the immunoprecipitated proteins.
Figure 4: MDH activity of the YFP-cytMDH construct. NSC-34 cells were transfected with YFP-MDH (black circles) or YFP (blank circles) expression plasmids. After 48 hours cells were lysed and aliquots containing 25μg protein were removed for assessment of MDH activity as measured by the decrease in NADH (OD
340nm) associated with conversion of oxaloacetate to malate.
Figure 5: WT-hSODl-GFP and G93A-hSODl-GFP cells were treated for 48h with vehicle (non-induced) or doxycycline (induced) to induce hSODl expression. A) Expression of cytMDH was measured by RT-PCR relative to that of the housekeeping gene GAPDH. B) and C) MDH activity was measured in the non-induced and induced WT-hSODl-GFP (B) and G93-A-hSODl-GFP (C) cells. * indicates p<0.05 compared to non-induced control.
Figure 6: WT-hSODl-GFP and G93A-hSODl-GFP cells were treated for 48h with vehicle (non-induced) or doxycycline (induced) to induce hSODl expression. Malate (A) and Lactate (B) levels were assessed in solubilized cells and expressed in mg/mg cell protein. * indicates p<0.05 compared to non-induced control. Figure 7: WT-hSODl-GFP and G93A-hSODl-GFP cells were treated for 48h with vehicle (non-induced) or doxycycline (induced) to induce hSODl expression.
Cytosol (A) and mitochondrial (B) fractions were prepared and analyzed for NAD+ and NADH contents. Results were normalized per protein content of the samples. ** indicates p<0.01 compared to non-induced control.
Figure 8: Model of malate dehydrogenase. The identified peptide is highlighted in yellow, the monomeric units of MDHl are in blue and green. NADH is represented in sticks and balls model.
Figure 9: FACS analysis of A) NSC-34 cells transfected with G93A-hSODl- CFP plasmid and YFP-expressing plasmid (negative FRET control). B) NSC-34 cells transfected with G93A-hSODl-CFP and cytMDH-YFP expression plasmids (positive
FRET control). C) NSC-34 cells co-transfected with G93A-hSODl-CFP /cytMDH-
YFP expression plasmids and myc-tagged peptide 217-239 expression plasmids
(negative FRET). D) NSC-34 cells co-transfected with G93A-hSODl-CFP /cytMDH- YFP expression plasmids and myc-tagged peptide 14-27 expression plasmid (positive
FRET). Excitation-405nm, Emission- 530nm.
Figure 10: Effect of peptide 217-239 on cell survival in rotenone- challenged WT-hSODl-GFP- and G93A-hSODl-GFP-expressing NSC-34 cells.
Cells were incubated for 24h with doxycycline and then for 4 hours with vehicle (solid bars) or 1 micromol/L peptide (hollow bars). A) 0.5 micromol/liter rotenone was added and incubation resumed for 24 hours. B) Medium was then replaced with
DMEM containing 5% serum and lmg/ml glucose with vehicle (solid bars), and 1 micromol/L peptide (hollow bars) for 72 hours. Viability was assessed by the methylene blue assay. * indicates significant difference between levels in the presence and absence of peptide (t-test).
Figure 11: Effects of octanoic acid on cell survival in rotenone-challenged WT-hSODl-GFP- and G93A-hSODl-GFP-expressing NSC-34 cells. A) Cells were incubated for 24h with doxycycline and then for (i) 24 hours in the presence of rotenone (1.25 micromol/liter) + vehicle (solid bars), or (ii) rotenone + 3mM octanoic acid (hollow bars). B) Cells were incubated with 3mM octanoic acid or vehicle and medium replaced with low (1 mg/ml) glucose in DMEM with 5% serum for 72 hours. Cell survival was then assessed. Viability was assessed by methylene blue assay. * indicates significant difference between wild-type and mutant cell levels (t-test).
DESCRIPTION OF THE PREFERRED EMBODIMENTS
The present invention provides methods of treating neurodegenerative disorders such as ALS in a subject, comprising the step of administering to the subject an agent capable of reducing an interaction between a malate dehydrogenase protein and an SODl protein. The present invention also provides methods of identifying an agent capable of treating ALS, comprising testing agents for ability to disrupt or prevent formation of a malate dehydrogenase-SODl complex, and methods of treating neurodegenerative disorders that are caused by complex formation of other a conformationally altered or mutant neurodegenerative disease-causing proteins with cytosolic malate dehydrogenase.
In one embodiment, the present invention provides a method of treating a neurodegenerative disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an agent capable of reducing an interaction between malate dehydrogenase and a conformationally altered or mutant protein, thereby treating a neurodegenerative disorder caused by complex formation of cytosolic malate dehydrogenase with a conformationally altered or mutant-causing protein. In another embodiment, the neurodegenerative disorder is amyotrophic lateral sclerosis (ALS). In another embodiment, the conformationally altered or mutant protein is a mutant SODl protein. In another embodiment, the mutant SODl protein is associated with ALS. In another embodiment, the agent is a peptide. In another embodiment, the agent is any peptide of the present invention. Each possibility represents a separate embodiment of the present invention. In another embodiment, the present invention provides a method of treating a neurodegenerative disorder, the method comprising administering to an individual in need thereof a therapeutically effective amount of an agent capable of increasing brain mitochondrial respiration, thereby treating the neurodegenerative disorder, with the proviso that said agent is not pyruate or oxaloacetate. In another embodiment, the agent is capable of increasing cytoplasmic malate levels in a subject in need thereof. In another embodiment, the agent is a peptide agent. In another embodiment, the peptide agent comprises at least 4 amino acids of human malate dehydrogenase. In another embodiment, the agent comprises the sequence set forth in SEQ ID NO: 1. In another embodiment, the agent is any peptide of the present invention. Each possibility represents a separate embodiment of the present invention.
The agent of methods and compositions of the present invention is, in another embodiment, a peptide. In another embodiment, the peptide comprises a fragment of a malate dehydrogenase protein. In another embodiment, the malate dehydrogenase is a human malate dehydrogenase. In another embodiment, the malate dehydrogenase is any other malate dehydrogenase known in the art. Each possibility represents a separate embodiment of the present invention. The ALS or neurodegenerative disorder treated by methods and compositions of the present invention is, in another embodiment, associated with a mutation in the gene encoding the human copper-zinc superoxide dismutase (hSODl) protein. In another embodiment, the ALS or neurodegenerative disorder is caused by a mutation in the hSOD gene. In another embodiment, the hSOD mutation is a gain-of-function mutation. In another embodiment, the hSOD mutation is a toxic gain-of-function mutation. In another embodiment, the ALS or neurodegenerative disorder is of unknown etiology. Each possibility represents a separate embodiment of the present invention.
In another embodiment, the fragment of malate dehydrogenase is 4 amino acids in length. In another embodiment, the fragment is at least 3 amino acids in length. In another embodiment, the fragment is at least 5 amino acids in length. In another embodiment, the fragment is at least 6 amino acids in length. In another embodiment, the fragment is at least 7 amino acids in length. In another embodiment, the fragment is at least 8 amino acids in length. In another embodiment, the fragment is at least 9 amino acids in length. In another embodiment, the fragment is at least 10 amino acids in length. In another embodiment, the fragment is at least 15 amino acids in length. In another embodiment, the fragment is at least 20 amino acids in length. In another embodiment, the fragment is at least 30 amino acids in length. In another embodiment, the fragment is at least 40 amino acids in length. Each possibility represents a separate embodiment of the present invention.
In another embodiment, the peptide comprises at least 4 consecutive amino acids of a malate dehydrogenase protein. In another embodiment, the peptide comprises at least 3 consecutive amino acids of a malate dehydrogenase protein. In another embodiment, the peptide comprises at least 5 consecutive amino acids of a malate dehydrogenase protein. In another embodiment, the peptide comprises at least 6 consecutive amino acids of a malate dehydrogenase protein. In another embodiment, the peptide comprises at least 7 consecutive amino acids of a malate dehydrogenase protein. In another embodiment, the peptide comprises at least 8 consecutive amino acids of a malate dehydrogenase protein. In another embodiment, the peptide comprises at least 9 consecutive amino acids of a malate dehydrogenase protein. In another embodiment, the peptide comprises at least 10 consecutive amino acids of a malate dehydrogenase protein. In another embodiment, the peptide comprises at least 15 consecutive amino acids of a malate dehydrogenase protein. In another embodiment, the peptide comprises at least 20 consecutive amino acids of a malate dehydrogenase protein. In another embodiment, the peptide comprises at least 30 consecutive amino acids of a malate dehydrogenase protein. In another embodiment, the peptide comprises at least 40 consecutive amino acids of a malate dehydrogenase protein. Each possibility represents a separate embodiment of the present invention.
A non-limiting example of a mutant SODl protein associated with ALS is G93A-hSODl. In another embodiment, the mutant SODl protein is any other mutant SODl protein associated with ALS known in the art. As described herein, the present invention provides methods readily generalizable by one skilled in the art to treatment of a neurodegenerative disorder such as ALS caused by any mutant SODl protein, particularly a mutant SODl that associates with MDH. The mutant SODl protein causing the disease need not be the same as that used in testing the agent. Since many mutant SODl proteins will interact with MDH in substantially the same manner, the same agents can be used for different mutant SODl proteins. Each possibility represents a separate embodiment of the present invention.
In another embodiment, the peptide comprises the dimerization site of MDHl with an SODl protein. In another embodiment, the peptide overlaps the dimerization site of MDHl with an SODl protein. In another embodiment, the peptide falls within the dimerization site of MDHl with an SODl protein. In another embodiment, the SODl protein is a mutant SODl protein. In another embodiment, the mutant SODl protein is associated with ALS. As a non-limiting example, the dimerization site of MDHl with G93A-hSODl is depicted herein in Figure 8. Each possibility represents a separate embodiment of the present invention.
In another embodiment, the peptide comprises the dimerization site of MDHl with another neurodegenerative disease-causing protein. In another embodiment, the peptide overlaps the dimerization site of MDHl with a neurodegenerative disease- causing protein. In another embodiment, the peptide falls within the dimerization site of MDHl with another neurodegenerative disease-causing protein. In another embodiment, the other neurodegenerative disease causing protein is a conformationally altered or mutant protein. In another embodiment, the conformationally altered or mutant protein is associated with a neurodegenerative disorder. Each possibility represents a separate embodiment of the present invention.
In another embodiment, the present invention provides a fragment of MDH of 19-50 amino acids in length, the peptide comprising the sequence set forth in SEQ ID NO: 1. In another embodiment, the MDH fragment is 19-45 amino acids in length. In another embodiment, the MDH fragment is 19-40 amino acids in length. In another embodiment, the MDH fragment is 19-35 amino acids in length. In another embodiment, the MDH fragment is 19-30 amino acids in length. In another embodiment, the MDH fragment is 19-25 amino acids in length. In another embodiment, the MDH fragment is 25-45 amino acids in length. In another embodiment, the MDH fragment is 25-40 amino acids in length. In another embodiment, the MDH fragment is 25-35 amino acids in length. In another embodiment, the MDH fragment is 25-30 amino acids in length. In another embodiment, an MDH-derived peptide of the present invention is derived from wt MDH. In another embodiment, the peptide is derived from a mutant MDH. Each possibility represents a separate embodiment of the present invention.
Another non-limiting example of a peptide that disrupts a MDH1-G93A- hSODl complex is a peptide with a sequence set forth in SEQ ID NO: 1. In another embodiment, a peptide of methods and compositions of the present invention comprises the sequence set forth in SEQ ID NO: 1. In another embodiment, a peptide of methods and compositions of the present invention has the sequence set forth in SEQ ID NO: 1. In another embodiment, the peptide overlaps the sequence set forth in SEQ ID NO: 1. In another embodiment, the overlap is at least 10 amino acids in length. In another embodiment, the overlap is at least 8 amino acids in length. In another embodiment, the overlap is at least 6 amino acids in length. In another embodiment, the overlap is at least 12 amino acids in length. In another embodiment, the overlap is at least 14 amino acids in length. In another embodiment, the overlap is at least 16 amino acids in length. In another embodiment, the overlap is at least 18 amino acids in length. Each possibility represents a separate embodiment of the present invention.
In another embodiment, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as an active ingredient, an agent capable of preventing an interaction between malate dehydrogenase and a conformationally altered or mutant protein, wherein the conformationally altered or mutant protein is associated with a neurodegenerative disorder. In another embodiment, the neurodegenerative disorder is amyotrophic lateral sclerosis (ALS). In another embodiment, the conformationally altered or mutant protein is an SODl protein. In another embodiment, the agent is a peptide agent. Each possibility represents a separate embodiment of the present invention.
In another embodiment, the agent of methods and compositions of the present invention is a small molecule. In another embodiment, the small molecule is selected from the group consisting of malate, octanoate, α-ketoglutarate, succinate and fumarate. In another embodiment, the small molecule is any other small molecule known in the art that is capable of up-regulating an activity of malate dehydrogenase. In another embodiment, the malate dehydrogenase is a cytosolic malate dehydrogenase. In another embodiment, the small molecule is any other small molecule known in the art that is capable of up-regulating acetyl coenzyme A. Each possibility represents a separate embodiment of the present invention. In another embodiment of methods and compositions of the present invention, the conformationally altered or mutant protein is associated with Parkinson's Disease. In another embodiment, the protein is Alpha-synuclein. In another embodiment, the protein is Parkin. In another embodiment, the protein is PINKl . In another embodiment, the protein is DJ-I. In another embodiment, the protein is ATPl 3 A2. In another embodiment, the protein is another protein for which mutations have been linked to Parkinson's disease. Each possibility represents a separate embodiment of the present invention. In another embodiment, the conformationally altered or mutant protein is associated with Alzheimer's disease. In another embodiment, the protein is amyloid beta peptide (ABETA). In another embodiment, the protein is another protein for which mutations have been linked to Alzheimer's disease. Each possibility represents a separate embodiment of the present invention.
In another embodiment, the conformationally altered or mutant protein is a protein known to contain poly-glutamine repeats. In another embodiment, the protein is Huntingtin, for which mutations of its gene are known to be associated with Huntington disease. In another embodiment, the protein is androgen receptor, for which mutations of its gene are known to be associated with Kennedy disease (also known as spinal and bulbar muscular atrophy). Each possibility represents a separate embodiment of the present invention.
In another embodiment, the conformationally altered or mutant protein is microtubule-associated protein tau. Mutations of the gene encoding tau have been linked to Alzheimer's and other neurodegenerative diseases, such as Pick's disease
(PID), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).
In another embodiment, the present invention provides a method of identifying an agent capable of treating amyotrophic lateral sclerosis (ALS), the method comprising the steps of (a) contacting said agent with a known initial amount of a complex of a malate dehydrogenase protein and a mutant SODl protein, wherein said mutant SODl protein is associated with ALS; and measuring an amount of said complex in the presence of said agent, whereby, if said amount of said complex in the presence of said agent is less than said known initial amount, then said agent is capable of treating amyotrophic lateral sclerosis.
In another embodiment, the present invention provides a method of identifying an agent capable of treating ALS, the method comprising the steps of: (a) contacting a malate dehydrogenase protein with a mutant SODl protein, wherein the mutant SODl protein is associated with ALS, in the presence of the agent; (b) measuring the amount of complex formation between the malate dehydrogenase protein and the mutant SODl protein, following step (a); (c) contacting the malate dehydrogenase protein with the mutant SODl protein in the absence of the agent; and (d) measuring the amount of complex formation between the malate dehydrogenase protein and the mutant SODl protein, following step (c), whereby, if the amount of step (b) is less than the amount of step (d), then the agent is capable of treating amyotrophic lateral sclerosis. In another embodiment, the present invention provides a method of identifying an agent capable of treating Parkinson's disease, the method comprising the steps of: (a) contacting a malate dehydrogenase protein with a mutant protein associated with Parkinson's disease, in the presence of the agent; (b) measuring the amount of complex formation between the malate dehydrogenase protein and the mutant protein, following step (a); (c) contacting the malate dehydrogenase protein with the mutant protein in the absence of the agent; and (d) measuring the amount of complex formation between the malate dehydrogenase protein and the mutant protein, following step (c), whereby, if the amount of step (b) is less than the amount of step (d), then the agent is capable of treating Parkinson's disease. In another embodiment, the mutant protein is Alpha-synuclein. In another embodiment, the mutant protein is Parkin. In another embodiment, the mutant protein is PINKl. In another embodiment, the mutant protein is DJ-I. In another embodiment, the mutant protein is ATP13A2. In another embodiment, the mutant protein is any other mutant protein known to be associated with Parkinson's disease. Each possibility represents a separate embodiment of the present invention.
In another embodiment, the present invention provides a method of identifying an agent capable of treating Alzheimer's disease, the method comprising the steps of: (a) contacting a malate dehydrogenase protein with a mutant protein associated with Alzheimer's disease, in the presence of the agent; (b) measuring the amount of complex formation between the malate dehydrogenase protein and the mutant protein, following step (a); (c) contacting the malate dehydrogenase protein with the mutant protein in the absence of the agent; and (d) measuring the amount of complex formation between the malate dehydrogenase protein and the mutant protein, following step (c), whereby, if the amount of step (b) is less than the amount of step (d), then the agent is capable of treating Alzheimer's disease. In another embodiment, the mutant protein is amyloid beta peptide (ABETA). In another embodiment, the mutant protein is any other mutant protein known to be associated with Alzheimer's disease. Each possibility represents a separate embodiment of the present invention. In another embodiment, the present invention provides a method of identifying an agent capable of treating Huntington disease, the method comprising the steps of: (a) contacting a malate dehydrogenase protein with a mutant protein associated with Huntington disease, in the presence of the agent; (b) measuring the amount of complex formation between the malate dehydrogenase protein and the mutant protein, following step (a); (c) contacting the malate dehydrogenase protein with the mutant protein in the absence of the agent; and (d) measuring the amount of complex formation between the malate dehydrogenase protein and the mutant protein, following step (c), whereby, if the amount of step (b) is less than the amount of step (d), then the agent is capable of treating Huntington disease. In another embodiment, the mutant protein is Huntingtin. In another embodiment, the mutant protein is another protein known to contain poly-glutamine repeats. In another embodiment, the mutant protein is any other mutant protein known to be associated with Huntington disease. Each possibility represents a separate embodiment of the present invention. In another embodiment, the present invention provides a method of identifying an agent capable of treating Kennedy disease (also known as spinal and bulbar muscular atrophy, the method comprising the steps of: (a) contacting a malate dehydrogenase protein with a mutant protein, wherein the mutant protein is associated with Kennedy disease, in the presence of the agent; (b) measuring the amount of complex formation between the malate dehydrogenase protein and the mutant protein, following step (a); (c) contacting the malate dehydrogenase protein with the mutant protein in the absence of the agent; and (d) measuring the amount of complex formation between the malate dehydrogenase protein and the mutant protein, following step (c), whereby, if the amount of step (b) is less than the amount of step (d), then the agent is capable of treating Kennedy disease. In another embodiment, the mutant protein is androgen receptor. In another embodiment, the mutant protein is another protein known to contain poly-glutamine repeats. In another embodiment, the mutant protein is any other mutant protein known to be associated with Kennedy disease. Each possibility represents a separate embodiment of the present invention. In another embodiment, the present invention provides a method of identifying an agent capable of treating a neurodegenerative disorder, the method comprising the steps of: (a) contacting a malate dehydrogenase protein with a mutant microtubule- associated protein tau, wherein the mutant tau protein is associated with the neurodegenerative disorder, in the presence of the agent; (b) measuring the amount of complex formation between the malate dehydrogenase protein and the mutant tau protein, following step (a); (c) contacting the malate dehydrogenase protein with the mutant tau protein in the absence of the agent; and (d) measuring the amount of complex formation between the malate dehydrogenase protein and the mutant tau protein, following step (c), whereby, if the amount of step (b) is less than the amount of step (d), then the agent is capable of treating the neurodegenerative disorder. In another embodiment, the neurodegenerative disorder is Alzheimer's disease. In another embodiment, the neurodegenerative disorder is Pick's disease (PID). In another embodiment, the neurodegenerative disorder is progressive supranuclear palsy (PSP). In another embodiment, the neurodegenerative disorder is corticobasal degeneration (CBD). In another embodiment, the neurodegenerative disorder is frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP- 17). In another embodiment, the neurodegenerative disorder is any other neurodegenerative disorder linked to a mutant tau protein. Each possibility represents a separate embodiment of the present invention.
In another embodiment, a complex of the present invention is fluorescently labeled. In another embodiment, the step of measuring an amount of a malate dehydrogenase-mutant SODl complex is performed by measuring a signal from the complex. In another embodiment, the signal is fluorescence signal. In another embodiment, the signal is a FRET signal. In another embodiment, an alteration in the signal is measured following addition of the test agent. In another embodiment, the signal is generated using FRET. In another embodiment, the signal is any other type of signal known in the art that can be engineered to be dependent on an intact malate dehydrogenase-mutant SODl complex. As described herein, the present invention provides methods readily generalizable by one skilled in the art to any type of quantitative or semi-quantitative signal that can be engineered to be dependent on an intact malate dehydrogenase-mutant SODl complex. Each possibility represents a separate embodiment of the present invention. Embodiments of the present invention provide agents and method of using same for treating neurodegenerative disorders, such as ALS. In some embodiments the agents are peptide agents such as peptides or small molecules which can interfere with binding of cytoplasmic malate dehydrogenase to ALS-related SODl or abrogating the inhibition of the malate-aspartate shuttle in the neurons. Additional embodiments of the present invention provide novel methods of screening for agents capable of interfering with binding of cytoplasmic malate dehydrogenase to SODl.
The term "peptide" as used herein encompasses native peptides (either degradation products, synthetically synthesized peptides or recombinant peptides) and peptidomimetics (typically, synthetically synthesized peptides), as well as peptoids and semipeptoids which are peptide analogs, which may have, for example, modifications rendering the peptides more stable while in a body or more capable of penetrating into cells. Such modifications include, but are not limited to N terminus modification, C terminus modification, peptide bond modification, including, but not limited to, CH2-NH, CH2-S, CH2-S=O, O=C-NH, CH2-O, CH2-CH2, S=C-NH,
CH=CH or CF=CH, backbone modifications, and residue modification. Methods for preparing peptidomimetic compounds are well known in the art and are specified, for example, in Quantitative Drug Design, CA. Ramsden Gd., Chapter 17.2, F. Choplin Pergamon Press (1992), which is incorporated by reference as if fully set forth herein.
Further details in this respect are provided herein below.
Peptide bonds (-CO-NH-) within the peptide may be substituted, for example, by N-methylated bonds (-N(CH3)-CO-), ester bonds (-C(R)H-C-O-O-C(R)-N-), ketomethylene bonds (-CO-CH2-), α-aza bonds (-NH-N(R)-CO-), wherein R is any alkyl, e.g., methyl, carba bonds (-CH2-NH-), hydroxyethylene bonds (-CH(OH)-CH2- ), thioamide bonds (-CS-NH-), olefinic double bonds (-CH=CH-), retro amide bonds (-NH-C0-), peptide derivatives (-N(R)-CH2-CO-), wherein R is the "normal" side chain, naturally presented on the carbon atom.
These modifications can occur at any of the bonds along the peptide chain and even at several (2-3) at the same time.
Natural aromatic amino acids, Trp, Tyr and Phe, may be substituted by synthetic non-natural acid such as TIC, naphthylalanine (NoI), ring-methylated derivatives of Phe, halogenated derivatives of Phe or o-methyl-Tyr.
In addition to the above, the peptides of the present invention may also include one or more modified amino acids or one or more non-amino acid monomers (e.g. fatty acids, complex carbohydrates etc). The term "amino acid" or "amino acids" is understood to include the 20 naturally occurring amino acids; those amino acids often modified post-translationally in vivo, including, for example, hydroxyproline, phosphoserine and phosphothreonine; and other unusual amino acids including, but not limited to, 2- aminoadipic acid, hydroxylysine, isodesmosine, nor-valine, nor-leucine and ornithine. Furthermore, the term "amino acid" includes both D- and L-amino acids.
Tables 1 and 2 below list naturally occurring amino acids (Table 1) and non- conventional or modified amino acids (Table 2) which can be used with the present invention.
Table 1
Figure imgf000019_0001
Table 2
Figure imgf000019_0002
Figure imgf000020_0001
Figure imgf000021_0001
Figure imgf000022_0001
Figure imgf000023_0001
Figure imgf000024_0001
The peptides of the present invention are preferably utilized in a linear form, although it will be appreciated that in cases where cyclization does not severely interfere with peptide characteristics, cyclic forms of the peptide can also be utilized. The peptides of the present invention may be synthesized by any techniques that are known to those skilled in the art of peptide synthesis. For solid phase peptide synthesis, a summary of the many techniques may be found in J. M. Stewart and J. D. Young, Solid Phase Peptide Synthesis, W. H. Freeman Co. (San Francisco), 1963 and J. Meienhofer, Hormonal Proteins and Peptides, vol. 2, p. 46, Academic Press (New York), 1973. For classical solution synthesis see G. Schroder and K. Lupke, The Peptides, vol. 1, Academic Press (New York), 1965.
In general, these methods comprise the sequential addition of one or more amino acids or suitably protected amino acids to a growing peptide chain. Normally, either the amino or carboxyl group of the first amino acid is protected by a suitable protecting group. The protected or derivatized amino acid can then either be attached to an inert solid support or utilized in solution by adding the next amino acid in the sequence having the complimentary (amino or carboxyl) group suitably protected, under conditions suitable for forming the amide linkage. The protecting group is then removed from this newly added amino acid residue and the next amino acid (suitably protected) is then added, and so forth. After all the desired amino acids have been linked in the proper sequence, any remaining protecting groups (and any solid support) are removed sequentially or concurrently, to afford the final peptide compound. By simple modification of this general procedure, it is possible to add more than one amino acid at a time to a growing chain, for example, by coupling (under conditions which do not racemize chiral centers) a protected tripeptide with a properly protected dipeptide to form, after deprotection, a pentapeptide. Further description of peptide synthesis is disclosed in U.S. Pat. No. 6,472,505.
A preferred method of preparing the peptide compounds of the present invention involves solid phase peptide synthesis.
Large scale peptide synthesis is described by Andersson Biopolymers 2000;55(3):227-50.
The peptides of the present invention may be delivered to the subject using gene therapy techniques or as peptide molecules. It will be appreciated that since the agents of the present invention are peptides they are susceptible to break-down by the enzymes in the stomach. In order to improve drug delivery therefore, the peptide agents of the present invention may be combined with a mucoadhesive agent. Various mucoadhesive agents, e.g., mucoadhesive polymers are known which are believed to bind to the mucus layers coating the stomach and other regions of the gastrointestinal tract. Examples of mucoadhesive polymers as discussed herein include, but are not limited to chitosan, polyacrylic acid, hydroxypropyl methylcellulose and hyaluronic acid. Most preferably, the mucoadhesive polymer is chitosan [Guggi et al., (2003) J of Controlled Release 92:125-135]. It will further be appreciated that delivery of peptide agents to the brain is restricted by the blood brain barrier. Over the years, several strategies to circumvent the blood brain barrier have been proposed, such as by transient osmotic opening of the BBB, high dosing (e.g., of chemotherapy), use of carrier systems such as antibodies, or even biodegradable implants. All these systems are contemplated by the present invention.
Furthermore, several synthetic NP polymers, arranged as spheres have been studied as carriers of drugs across the BBB. Poly(butyl cyanoacrylate) has been reported to effectively deliver different drugs, including peptides [Kreuter J. Adv. Drug Delivery Rev. 2001, 47:65-81 ; Gulayev AE, et al., Pharm Res 1999, 16: 1564-9]. It has also been suggested that liposomes can enhance drug delivery to the brain across the blood-brain barrier [Umezawa and Eto, Biochem. Biophys. Res. Comm. 153:1038-1044 (1988); Chan et al, Ann. Neurol, 21 :540-547 (1987); Laham et al, Life Sciences 40:2011-2016 (1987); and Yagi et al, J. APRIo Biocheme 4:121-125 (1982)]. Liposomes are small vesicles (usually submicron sized) comprised of one or more concentric bilayers of phospholipids separated by aqueous compartments. It has been suggested that the use of an external ligand such as mannose can improve a liposomal particle's ability to cross the BBB [Huitinga et al, J exp Med 172 (1990) 1025-33; Umezawa F., Biochem Biophys Res Commun 153 (1988) 1038-44]. The mannosylated liposomes were shown to be incorporated in glial cells as opposed to neuronal cells, the former having a receptor for mannose [Umezawa F., Biochem Biophys Res Commun 153, 1988, 1038-44]. PCT Application, Publication No. WO9402178A1 to Micklus discusses the coupling of liposomes to an antibody binding fragment which binds to a receptor molecule present on the vascular endothelial cells of the mammalian blood-brain barrier. The peptides perhaps may also be delivered by phages, or in a liquid or solid formulation, intranasally for example. The peptides or small molecules of the present invention may be used to treat neurodegenerative disorders. Examples of neurodegenerative disorders include, but are not limited to Amyotrophic lateral sclerosis (ALS), Alzheimer's Dementia, Alexander disease, Alper's disease, Ataxia telangiectasia, Batten disease, Bovine spongiform encephalopathy (BSE), Canavan disease, Cockayne syndrome, Corticobasal degeneration, Creutzfeldt-Jakob disease, Huntington disease, HIV- associated dementia, Kennedy's disease, Krabbe disease, Lewy body dementia, Machado- Joseph disease (Spinocerebellar ataxia type 3), Multiple sclerosis, Multiple System Atrophy, Neuroborreliosis, Parkinson disease, Pelizaeus-Merzbacher Disease, Pick's disease, Primary lateral sclerosis, Prion diseases, Refsum's disease, Sandhoff disease, Schilder's disease, Schizophrenia, Spielmeyer-Vogt-Sjogren-Batten disease, Spinocerebellar ataxia and Spinal muscular atrophy.
The peptides or small molecule agents of the present invention may be delivered to the subject per se or as part of a pharmaceutical composition.
As used herein a "pharmaceutical composition" refers to a preparation of one or more of the active ingredients described herein with other chemical components such as physiologically suitable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.
Herein the term "active ingredient" refers to the DJ-I peptides of the present invention accountable for the biological effect. Hereinafter, the phrases "physiologically acceptable carrier" and
"pharmaceutically acceptable carrier" which may be interchangeably used refer to a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound. An adjuvant is included under these phrases. Herein the term "excipient" refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient. Examples, without limitation, of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols. Pharmaceutical compositions of the present invention may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
Pharmaceutical compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active ingredients into preparations which, can be used pharmaceutically.
Proper formulation is dependent upon the route of administration chosen.
For injection, the active ingredients of the pharmaceutical composition may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological salt buffer.
Herein the term "excipient" refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient.
Examples, without limitation, of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols. Techniques for formulation and administration of drugs may be found in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, PA, latest edition, which is incorporated herein by reference.
Suitable routes of administration may, for example, include oral, rectal, transmucosal, especially transnasal, intestinal or parenteral delivery, including intramuscular, subcutaneous and intramedullary injections as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections.
Alternately, one may administer the pharmaceutical composition in a local rather than systemic manner, for example, via injection of the pharmaceutical composition directly into a tissue region of a patient i.e. the brain.
Pharmaceutical compositions of the present invention may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
Pharmaceutical compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active ingredients into preparations which, can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
For injection, the active ingredients of the pharmaceutical composition may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological salt buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
The pharmaceutical composition described herein may be formulated for parenteral administration, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multidose containers with optionally, an added preservative. The compositions may be suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Pharmaceutical compositions for parenteral administration include aqueous solutions of the active preparation in water-soluble form. Additionally, suspensions of the active ingredients may be prepared as appropriate oily or water based injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acids esters such as ethyl oleate, triglycerides or liposomes.
Aqueous injection suspensions may contain substances, which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol or dextran.
Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the active ingredients to allow for the preparation of highly concentrated solutions.
Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water based solution, before use.
Pharmaceutical compositions suitable for use in context of the present invention include compositions wherein the active ingredients are contained in an amount effective to achieve the intended purpose. More specifically, a therapeutically effective amount means an amount of active ingredients effective to prevent, alleviate or ameliorate symptoms of a disorder (e.g., neurodegenerative disorder) or prolong the survival of the subject being treated.
Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
For any preparation used in the methods of the invention, the therapeutically effective amount or dose can be estimated from animal models to achieve a desired concentration or titer. Such information can be used to more accurately determine useful doses in humans.
Toxicity and therapeutic efficacy of the active ingredients described herein can be determined by standard pharmaceutical procedures in experimental animals. The data obtained from these animal studies can be used in formulating a range of dosage for use in human. The dosage may vary depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g., Fingl, et al., 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 p.l).
Dosage amount and interval may be adjusted individually to provide cell numbers sufficient to induce normoglycemia (minimal effective concentration, MEC). The MEC will vary for each preparation, but can be estimated from in vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. Detection assays can be used to determine plasma concentrations.
The amount of a composition to be administered will, of course, be dependent on the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician, etc.
Compositions of the present invention may, if desired, be presented in a pack or dispenser device, such as an FDA-approved kit, which may contain one or more unit dosage forms containing the active ingredient. The pack may, for example, comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also be accommodated by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or human or veterinary administration. Such notice, for example, may be of labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert. Compositions comprising a preparation of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition, as if further detailed above.
EXPERIMENTAL DETAILS SECTION
Reference is now made to the following examples, which together with the above descriptions, illustrate the invention in a non limiting fashion.
Generally, the nomenclature used herein and the laboratory procedures utilized in the present invention include molecular, biochemical, microbiological and recombinant DNA techniques. Such techniques are thoroughly explained in the literature. See, for example, "Molecular Cloning: A laboratory Manual" Sambrook et al., (1989); "Current Protocols in Molecular Biology" Volumes I-III Ausubel, R. M., ed. (1994); Ausubel et al., "Current Protocols in Molecular Biology", John Wiley and Sons, Baltimore, Maryland (1989); Perbal, "A Practical Guide to Molecular Cloning", John Wiley & Sons, New York (1988); Watson et al., "Recombinant DNA", Scientific American Books, New York; Birren et al. (eds) "Genome Analysis: A Laboratory Manual Series", VoIs. 1-4, Cold Spring Harbor Laboratory Press, New York (1998); methodologies as set forth in U.S. Pat. Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057; "Cell Biology: A Laboratory Handbook", Volumes I-III Cellis, J. E., ed. (1994); "Culture of Animal Cells - A Manual of Basic Technique" by Freshney, Wiley-Liss, N. Y. (1994), Third Edition; "Current Protocols in Immunology" Volumes I-III Coligan J. E., ed. (1994); Stites et al. (eds), "Basic and Clinical Immunology" (8th Edition), Appleton & Lange, Norwalk, CT (1994); Mishell and Shiigi (eds), "Selected Methods in Cellular Immunology", W. H. Freeman and Co., New York (1980); available immunoassays are extensively described in the patent and scientific literature, see, for example, U.S. Pat. Nos. 3,791,932; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876; 4,879,219; 5,011,771 and 5,281,521; "Oligonucleotide Synthesis" Gait, M. J., ed. (1984); "Nucleic Acid Hybridization" Hames, B. D., and Higgins S. J., eds. (1985); "Transcription and Translation" Hames, B. D., and Higgins S. J., eds. (1984); "Animal Cell Culture" Freshney, R. L, ed. (1986); "Immobilized Cells and Enzymes" IRL Press, (1986); "A Practical Guide to Molecular Cloning" Perbal, B., (1984) and "Methods in Enzymology" Vol. 1-317, Academic Press; "PCR Protocols: A Guide To Methods And Applications", Academic Press, San Diego, CA (1990); Marshak et al., "Strategies for Protein Purification and Characterization - A Laboratory Course Manual" CSHL Press (1996); all of which are incorporated by reference as if fully set forth herein. Other general references are provided throughout this document. The procedures therein are believed to be well known in the art and are provided for the convenience of the reader. All the information contained therein is incorporated herein by reference. EXAMPLES Materials
Dulbecco's modification of Earle's medium (DMEM), heat-inactivated fetal calf serum (FCS), L-glutamine, penicillin streptomycin and EZ- First Strand cDNA Synthesis RNA kit, L-glutamine, G418 and antibiotics were obtained from Biological Industries (Beit Haemek, Israel); Doxycyclin, thiazol blue (MTT), alcohol dehydrogenase, PES, Hygromycin B NADH and NAD from Sigma (Sigma-Aldrich, St. Louis, MO); Lipofectamin 2000 from Invitrogen (San Diego, CA); (rabbit) anti- human SODl antibodies from Santa Cruz, Inc. (USA); polyclonal (rabbit) anti-GFP, from Abeam (UK); goat anti rabbit-IRDey-800 from Li-Cor; Taq DNA polymerase from Bioline (Luckenwalde, Germany); SMART cDNA synthesis kit pEGFP pECFP, pEYFP and pTRE2hyg plasmids from Clonetech; malic and lactic acid determination kits from ENZYTEC (Germany); μ-slide 8 well plates from Ibidi (Germany); protein A-sepharose from Amersham Bioscience; Ampicillin from Applichem; and pQBI25 fcl,2,3from (Qbiogene/ MP Biomedicals [Irvine, California]).
Stable cell lines expressing inducible forms of G93A-hSODl-GFP and WT- hSODl-GFP
NSC-34 cells were provided by Dr. Neil Cashman. pcDNA3.1 plasmids containing wild-type or G93A-mutant hSODl cDNA were provided by Dr. David Gozal. NSC- 34 cell lines stably expressing an inducible form of WT-hSODl or G93A-hSODl fused with GFP at the C-terminal end were obtained by cotransfection with pUHD 172-1 and pTRE2hyg-WT-hSODl-GFP or pTRE2hyg-G93A-hSODl-GFP cDNA.
Cell culture NSC-34 cells were grown in DMEM supplemented with 5% heat-inactivated
FCS, ImM glutamine, and antibiotics (100 IU/mL penicillin and 100 μg/mL streptomycin) at 37 °C in a 5% CO2 humidified atmosphere. WT-hSODl and G93A- hSODl cell lines were kept in selection by addition of G418 (700μg/mL) plus hygromycin B (200 ug/mL) until used. Cells were incubated with doxycycline (1 μg/mL; 24 h) to induce expression of WT-hSODl-GFP and G93A-hSODl-GFP proteins. Mouse Spinal Cord and Motor Cortex cDNA Library construction.
Freshly excised brains and spinal cords of C57 black mice that were sacrificed for another research project were donated by Dr D M Michaelson. Total RNA was prepared from the freshly excised tissues using EZ-RNA preparation kit. Aliquots (lug) of total RNA were subjected to cDNA synthesis using the SMART cDNA synthesis kit according to user manual. The first strand was subjected to PCR amplification using a primer 5'-
CCTAGCGGCCGCAAGCAGTGGTATCAACGCAGAGT-S' (SEQ ID NO: 3) that included a Notl restriction site. The cDNA was digested with Notl and subjected to ligation with a set of 3 vectors pQBI25 fc 1,2,3 that contains the blue fluorescence protein (BFP) encoding sequence. Ligation products were electroporated into DH5α bacteria, to obtain l*10A6 clones.
To assess library variability, a representative amount of colonies from the transformed DH5α, were subjected to PCR analysis using the following primers: Forward 5'-CATTACCTGTCCACACAATCTGCCC-3l (SEQ ID NO: 4) Reverse 5'- CACCTACTCAGACAATGCGATGC-3' (SEQ ID NO: 5). The library was amplified overnight in 2XTY media containing ampicillin. Bacterial pellets were collected by centrifugation and suspended in 5ml of 2XTY + 15% glycerol and frozen at -700C until use. FRET analysis
Construction of pQBI -BFP-GFP plasmid: A plasmid containing a BFP-GFP chimera was prepared in order to serve as a positive control for the FRET studies. pQBI25 plasmid was digested with CIaI and Notl. pEGFP plasmid was used to obtain GFP DNA by PCR amplification using the following primers: Forward 5'- CTCAGATATCGATCTCAAGCTO1 (SEQ ID NO: 6) Reverse 5'- CCTCTACAAATGTGGTATGGCTG-3' (SEQ ID NO: 7). The GFP DNA was digested with CIaI and Notl and subjected to ligation with the pQBI25 plasmid with a 23 amino acid linker.
FRET Live Cell Screening: The mouse cDNA library, the pQBI -BFP-GFP and pQBI plasmids were transfected into the WT-hSODl-GFP and G93A-hSODl-
GFP cells using lipofectamine transfection reagent. After 24h, lug/ml doxycycline was added to induce expression of the hSODl-GFP chimera. 24h later, cells were washed with PBS harvested and analyzed by fluorescence activated cell sorting (FACS) using an excitation UV laser set at 0.133 W and a 530/30 nm emission filter. pQBI -BFP-GFP transfected NSC-34 cells and pQBI -BFP-GFP transfected WT-hSODl-GFP and G93A-hSODl-GFP cells were used to identify cells with positive FRET signal. pQBI25 (which contains the BFP) transfected WT-hSODl- GFP and G93A-hSODl-GFP were used to evaluate FRET signals coming from interactions between the BFP and GFP moieties. The gating area was set on the population defined by a positive FRET signal. The WT-hSODl-GFP and G93A hSODl-GFP cells transfected with the mouse spinal cord and motor cortex library were subjected to FACS to sort out cells showing a positive FRET signal.
Total RNA was extracted from each of the sorted cells and subjected to RT using EZ- First Strand cDNA Synthesis RNA kit followed by PCR amplification with the following primers: Forward 5t-CATTACCTGTCCACACAATCTGCCC-3l (SEQ ID NO: 8) Reverse 5 '-C ACCTACTC AGAC AATGCGATGC-31 (SEQ ID NO: 9). PCR products were digested with Notl and recloned into pQBI50fcl,2,3 plasmids. Of these clones 60 individual clones were sequenced. The clones that appeared repeatedly in the G93A-hSODl but not WT-hSODl were selected for further confocal FRET and co-immunoprecipitation studies.
Confocal FRET analysis YFP CFP fluorophores plasmids: The pECFP plasmid containing the CFP
(cyan fluorescence protein) was digested with Agel and HindIII and subjected to ligation with the pcDNA3.1 plasmids containing WT-hSODl and G93A-hSODl cDNA. A set of 3 vectors pEYFP fc 1,2,3 containing Notl restriction site were prepared. Thus, pEYFP was digested with EcoRI and BamHI and subjected to ligation with 3 pairs of frame-shifted oligonucleotides, each containing Notl and EcoRV sites with the following sequences:
Frame 1 Sense 51-AATTCTGCGATATCGCGGCCGCG-3l (SEQ ID NO: 10); Anti sense 5'-GATCCGCGGCCGCGATATCGCA-S' (SEQ ID NO: 11); Frame 2 sense 5'-AATTCTGCCGATATCGCGGCCGCG-S' (SEQ ID NO: 12); anti sense 5'-GATCCGCGGCCGCGATATCGGCA-3I (SEQ ID NO: 13);
Frame 3 sense 5'-AATTCTGCCCGATACGCGGCCGCG-S' (SEQ ID NO: 14); anti sense 51-GATCCGCGGCCGCGATATCGGGCA-3l (SEQ ID NO: 15).
Selected clones from the FACS sorted FRET positive clones were cloned into the suitable pEYFP vector to yield a pEYFP-derivative of the selected clones and subjected to confocal FRET analysis. Confocal FRET analysis: l*10Λ5 NSC-34 cells/ well were plated in a μ-slide
8 wells slide. Cells were transfected with pECFP-G93A-hSODl and pECFP-WT- hSODl with and without pEYFP-derivative of the selected clones. In addition, cells were transfected with pEYFP-derivative of the selected clones or the control pEYFP alone. Transfected cells were grown for 48h and subjected to ZEISS confocal microscopy. Emission spectra of CFP and YFP were collected using laser excitation of 405 and 514nm respectively, and an emission window of lOnm between 449 to 599 for the CFP excitation and an emission window of lOnm between 524 to 599 for the YFP excitation. The FRET efficiency was calculated as described (14). One clone expressing cytosolic malate dehydrogenase (cytMDH) showed a high FRET efficiency and was chosen for further co-immunoprecipitation studies.
Pull-down immunoprecipitation
NSC-34 cells were cotransfected with pCDNA3.1-WT-hSODl and pEYFP-cytMDH or with pCDNA3.1-G93A-hSODl and pEYFP-cytMDH. After 48 hours cells were lysed in solubilization buffer (5OmM Hepes PH7.5, 150 mM NaCl, 10% glycerol, 1% Triton -X, 1 mM EDTA, 1 Mm EGTA and 1.5 mM MgCl2). Samples containing 0.5 mg protein were subjected to immunoprecipitation using anti hSODl antibodies immobilized on protein A-coupled sepharose beads. The beads were washed and proteins were solubilized in SDS loading buffer. Samples were boiled for 3min and subjected to SDS 7.5% polyacrylamide gel electrophoresis and immunoblotting. Immunoblotting and quantification of SODl derivatives and YFP-tagged MDH
Cells were solubilized in 5OmM Hepes buffer pH-7.5 containing 15OmM NaCl, 10% glycerol, 1% Triton X-100, ImM EDTA, ImM EGTA and 1.5mM MgC12). Cell lysates were diluted with sodium dodecyl sulfate (SDS) loading buffer. The mixture was boiled for 3 min and stored at -80°C for subsequent analysis. Proteins (100 μg per lane) were subjected to 7.5% (v/v) SDS-polyacrylamide gel electrophoresis and the resolved proteins were electroblotted onto nitrocellulose membranes. Nonspecific binding sites on the nitrocellulose membranes were blocked by incubation for 1 h with 5% (w/v) non-fat milk in Tris-buffered saline (TBST), containing 150 mM NaCl, 1O mM Tris-HCl, pH 7.4, and 0.1% (v/v) Tween-20. The nitrocellulose membranes were incubated overnight at 4°C with primary antibodies (anti human SODl; anti- GFP; anti- β-actin) diluted 1 :1000 in TBST with 1% (w/v) bovine serum albumin. After washing in TBST, the nitrocellulose membranes were incubated for 1 h at room temperature (20°C) with IRDey-800-linked secondary antibodies, diluted 1 : 10,000 in TBST, washed in TBST and subjected to analysis on the odyssey fluorescence reader from Li-Cor bioscience.
Preparation of mitochondria and cytosol fractions 3.5*10Λ6 G93A-hSODl-GFP and WT-hSODl-GFP cells were plated (12 plates of 10cm each). Doxycycline (lug/ml) was added after 24h to half of the plates and 48h later cells scraped off the plates, cells from each two plates were combined, collected by centrifugation. Cells pellets were suspended in 500ul of 1OmM Tris-HCl buffer pH-7.4 containing 25OmM sucrose, and 2mM EDTA. Cells were subjected to 3 rounds of freezing/thawing. 0.5gr of glass beads (60 mesh) were then added and tubes were vortexed 3 times and centrifuged (2000rpm 5min). The supernatants (containing the cytosol and mitochondria) were collected and centrifuged at 10,000 rpm for 15min. Supernatants (cytosol) and pellets (mitochondria) were collected. The pellets were suspended in 250ul of 1OmM Tris-HCl buffer pH-7.4 containing 25OmM sucrose, and 2mM EDTA containing 0.5% Tween.
Assessment of MDH enzymatic activity
Aliquots of the cytosolic fractions were incubated with 10OmM potassium phosphate buffer pH 7.4 containing 2 mM NADH. Reaction started with the edition of 1OmM oxaloacetate and the decrease in NADH was measured on 'ultraspec 2000' at 340nm for 3 min at 3 sec intervals.
Lactate and malate assays
Aliquots (10OuI) aliquots of the cytosol fractions were used for determinations of lactate and malate concentrations with Enzytec™ lactic and malic acids determination kits. NADH NAD+ measurements
NAD+ and NADH concentrations were measured by spectrophotometric enzymatic cycling assay as described (15). For NADH determination 50 μl aliquots the cytosol and mitochondrial suspensions were diluted in IN NaOH to yield 0.2N NaOH concentration and heated at 6O0C for 20min to destroy NAD+. For total NADH and NAD+ determination 50ul aliquots the cytosol and mitochondrial suspensions were diluted in IN NaOH to yield 0.2N NaOH concentration without heating. 15ul aliquots of the heated and non-heated samples were incubated with 200ul cycling assay mix, containing 10OmM Tris-HCl, 2mM PES 0.5 mM thiazol blue, 0.2mg/ml alcohol dehydrogenase and 0.6M ethanol at 37°C for 10 min. NAD+ Absorption was read at OD 570nm (Linear range 1- 8OnM NADH or NAD+).
Screening for peptide agents that inhibit the association of MDHl with disease proteins
The screening method was based on the fluorescence resonance energy transfer (FRET) system between cyan fluorescence protein (CFP) chimera proteins and yellow fluorescence protein (YFP) chimera proteins. The present inventors designed and used this system to identify the specific interaction of G93A SODl with MDHl so as to identify a motif within MDHl that is critical for the G93A SODl - MDHl interaction. The agents tested were peptides derived from MDHl. A Myc-tagged peptide library expressing small fragments of the MDHl was prepared. MDHl cDNA was digested with AIuI or/and Dpnl and the fragments were cloned so that each peptide was placed in the correct reading frame of the original protein and in frame to the human myc tag sequence. G93A SODl-CFP and MDHl- YFP expression plasmids were transfected into NSC-34 cells with and without the myc-tagged library.
The hypothesis is that the specific MDHl -derived peptides comprising the interacting motif will compete with MDHl for the G93A SODl-MDHl interaction site. In such case, the CFP and YFP fluorescence of the G93A SODl-CFP and MDHl-YFP will still be present, but the FRET signal will be diminished. The screening studies were performed using a cell sorter (FACS) with 405nm excitation laser and a 530/30nm emission filter. CFP tagged cells that showed no FRET signal were sorted out. RNA was extracted from the sorted cells, converted into cDNA and subjected to PCR amplification in order to amplify the peptides DNA sequences.
The DNA sequence from the sorted cells was re-cloned. Four clones were obtained, one corresponding to amino acids 14-27 of the cytMDH protein GQIAHSLLYSIGNG (SEQ ID NO: 2) and three corresponding to amino acids 217- 239 of the cytMDH protein SWLKGEFITTVQQRGAAVIKARK (SEQ ID NO: 1). The identified clones were re-analyzed in the FACS-based system to verify their ability to compete for the G93A SODl - MDHl interaction at 1:1 :1 ratio levels. Thus, 5*10A6 NSC-34 cells were transfected with equal amounts of G93A-hSODl-CFP and cytMDH- YFP and the suspected myc-tagged cytMDH peptide-expressing plasmids. Peptides that prevented the FRET, namely those that shifted the cell population toward the FRET negative gating area, were considered to impair the G93A-hSODl- CFP /cytMDH- YFP interaction.
Only one of two clones prevented the FRET under these conditions. The identified myc-tagged peptide was sequenced and identified as amino acids 217-239 of the cytMDH protein SWLKGEFITTVQQRGAAVIKARK (SEQ ID NO: 1).
Functional assays
The functional significance of the loss of such interaction was assessed by alleviation of the rotenone (a mitochondrial inhibitor) or low-glucose challenge in NSC-34 clones expressing an inducible form of the mutant G93A SODl-GFP as monitored by cell survival. The SWLKGEFITTVQQRGAAVIKARK (SEQ ID NO: 1) peptide was synthesized (SBS Gentech Beijing) with 5,6-TAMRA modification (to allow detection) at the N-terminus. The TAMRA-modified peptide was dissolved in 10% acetic acid and added to cell culture medium in culture medium containing 1% ethanol. Thus, 15,000 cells (WT-hSODl or G93A-hSODl) seeded in each well of a 96-well plate in DMEM, 10% serum. 24 hours later, cells were incubated with l*10Λ- 6M cytMDH peptide (or acetic acid/ethanol vehicle) for 4h without serum. 1-10 micromole/L Rotenone in DMEM, 10% serum was then added for 24 hours, or medium replaced with low glucose (1 mg/ml) in DMEM with 5% serum for 72 hours. Cell survival was then assessed. It was expected that if the identified peptide interaction is resolving the gain of toxic interaction of G93A SODl-GFP, then survival of the cells upon rotenone- or low-glucose challenge will improve. Determination of octanoic acid effect
15,000 cells (WT-hSODl or G93A-hSODl) were seeded in each well of a 96 well-plate in DMEM, 10% serum. 24 hours later, the cells were incubated with 3mM octanoic acid with and without 1-10 micromole/L rotenone in DMEM, 10% serum for 24 hours. Or, cells were incubated with 3mM octanoic acid and medium replaced with regular (5 mg/L) or low (1 mg/ml) glucose in DMEM with 5% serum for 72 hours.
Cell survival was then assessed. It was expected that if the gain of toxic interaction of
G93A SODl-GFP is due to inhibition of the malate-aspartate shuttle, octanoic acid will provide an alternative energy source through the alternative shunt and the survival of the cells upon rotenone or low-glucose challenge will improve.
Cell survival
Cell survival was assessed by the methylene blue assay. Cells were fixed with
4% formaldehyde solution for Ih, then washed with 0.1M sodium borate buffer pH8.5, stained with 1% methylene blue for 20min and washed with water. Cell-bound dye was eluted with 200 μl of 0.1 M HCl. The optical density was assessed at 595nm in ELISA plate reader.
RESULTS
EXAMPLE 1: FRET analysis reveals G93A-hSODl interaction with cytMDH For the initial screening, two motor neuron-derived cell lines (NSC-34) were used that were stably transfected with a gene that inducibly expresses the diseased (G93A) and WT hSODl genes fused with green fluorescent protein (GFP) at their C- terminal end, to be used as FRET acceptors. A cDNA chimera library was generated from mouse spinal and cortical motor neurons wherein the clones were fused with BFP at the N-terminal end, to be used as FRET donors. The screening studies were performed using a cell sorter (FACS) to collect cells showing positive FRET signals. In principle, emission of the acceptor (GFP) during donor (BFP) excitation should indicate a positive FRET signal and thus be interpreted as evidence of proximity of the donor- and acceptor-tagged proteins. However, because of overlap in GFP and BFP spectra, the measured GFP emission caused by FRET is always contaminated by both direct excitation of GFP and by BFP emission in the GFP range. To overcome these problems, a BFP-GFP chimera was first constructed to serve as a positive control for the FRET signal and set the FACS gating area on the population defined by a positive FRET signal. Figure 1 depicts FACS analysis of the BFP-GFP chimera and BFP expression plasmids transfected into the G93A-hSODl-GFP (Figure IA) and the parent NSC-34 (Figure IB) cell line. FACS analysis of the G93A-hSODl- GFP cells transfected with the GFP-BFP chimera reveals two distinct cell populations (Rl and R2). Only one of these populations (R2) is present in the parent NSC-34 cells transfected with the BFP-GFP chimera in the absence of the GFP-tagged hSODl, thus identifying Rl as contaminating (non-FRET) fluorescence from the GFP-tagged h- SODl protein. FACS analysis of the G93A-hSODl-GFP cells transfected with BFP (Figure 1C) revealed a single population of cells (Rl) that corresponded to the non- FRET fluorescence of the GFP fluorophore and no contaminating BFP emission. R2 was thus defined as a positive FRET population. This FRET-positive cell population is thus only generated when proteins from the BFP-tagged library are in close proximity with G93A-hSODl-GFP or WT-hSODl-GFP. The FACS gating area was thus set on the R2 population to sort out cells in which there is an apparent association between the hSODl-GFP derivatives and a BFP-tagged candidate protein from the mouse motor-cortex spinal cord library.
G93A-hSODl-GFP and WT-hSODl-GFP NSC-34 cells were transfected with the BFP-tagged library and induced to express the hSODl proteins. Single cells demonstrating a positive FRET signal were sorted out using FACS. The initial screening identified a number of FRET positive, candidate BFP-tagged proteins that appeared to differentially interact with G93A-hSODl-GFP but not WT-hSODl-GFP. The most frequently occurring ones were HSP-70, which has already been shown to interact with hSODl (16), myelin, aldolase-la, transferrin, the 3' end of kinesin-5a and cytosolic malate dehydrogenase (cytMDH).
EXAMPLE 2: Confirmation of G93A-hSODl-cytMDH interaction by confocal microscopy using a different fluorophore pair
The interaction between each of the candidate proteins and the G93A-hSODl and WT-hSODl proteins was further characterized at the single-cell level by confocal microscopy, this time using a different set of donor (CFP) and acceptor (YFP) fluorophores to exclude the possibility of identifying protein interactions driven by the fluorophores themselves. Expression plasmids encoding G93A-hSODl and WT- hSODl fused to CFP were prepared as FRET donors, and plasmids encoding YFP fused with each of the candidate interacting proteins were prepared as FRET acceptors. CFP was attached to the C-terminus of SODl, and YFP was attached to the N-terminal of the candidate protein. NSC-34 cells were transfected transiently with either G93A-hSODl or WT-hSODl fused to CFP expression plasmids and/or expression plasmids encoding YFP fused to candidate interacting proteins, and the interaction was assessed 48 hours later by FRET confocal microscopy. FRET was measured as enhanced emission of the acceptor (YFP) during donor (CFP) excitation. However, because of overlap in CFP and YFP spectra, measured YFP emission caused by FRET is contaminated by both direct excitation of YFP and by CFP emission in the YFP range. To overcome these limitations, FRET efficiency was quantified using spectrum measurements as described (14). Emission spectra were obtained upon excitation of the donor at 405 nm of cells expressing G93A-hSODl- CFP and YFP-tagged candidate protein (Fig. 2A, data set A). The FRET-related YFP emission (F405) was extracted by subtracting the CFP spectrum collected from control cells expressing the G93A-hSODl-CFP alone (Fig. 2A, data set B). The YFP spectrum upon direct excitation of the acceptor (F514) was also measured. The (F405/F514) ratio of the emission spectra obtained upon excitation at 405nm and 514nm of cells expressing G93A-hSODl-CFP and YFP-tagged candidate protein was calculated (RatioA; Fig 2B). Similarly the ratio (F405/F514) of the emission spectra obtained upon excitation at 405nm and 514nm of cells expressing only the YFP- tagged protein was calculated (RatioAO; Fig 2B). Because RatioA is not dependent on wavelength, it was used to check for significant contaminations by other fluorescence sources (14). The difference (RatioA - RatioAO), that is directly proportional to FRET efficiency, was evaluated as an indicator of proximity. Similar measurements were performed for cells expressing WT-hSODl-CFP and YFP-tagged candidate protein (Fig. 2C, data set A) and WT-hSODl-CFP alone (Fig. 2C, data set B). RatioA and RatioAO were assessed accordingly (Fig. 2D). Of the six candidate proteins identified in the screening only YFP-cytMDH demonstrated a positive FRET signal in this system with G93A-hSODl-CFP (Figs. 2A-B). No such signal was seen with WT- hSODl-CFP (Figs. 2C-D). Thus, as demonstrated in Fig 2, only the G93A SODl cytMDH-expressing cells exhibited emission within the acceptor emission wavelength after excitation with the donor excitation wavelength. EXAMPLE 3: Confirmation of G93A-hSODl-cytMDH interaction using co- immunoprecipitation
Co-immunoprecipitation studies were next performed to further confirm the G93A-hSODl cytMDH interaction. To avoid complex formation due to excess of one of the potentially interacting proteins, parent NSC-34 cells were co-transfected with equal amounts of untagged WT-hSODl or G93A-hSODl and cytMDH- YFP. Cells were lysed, and immunoprecipitation was performed with anti-hSODl antibody. The precipitated proteins were subjected to SDS gel electrophoresis followed by immunoblotting with anti GFP antibody. As depicted in Figure 3, comparable amounts of CFP-tagged G93A-hSODl and WT-hSODl vs. cytMDH- YFP were expressed. cytMDH- YFP was co-immunoprecipitated with G93A-hSODl but not with WT-hSODl, thus further confirming the cytMDH- YFP-G93A-hSODl interaction.
The YFP-tagged cytMDH retained normal function. This was shown by measurement of MDH activity in naive NSC-34 cells transfected with cytMDH- YFP
(exogenous MDH) and YFP alone (endogenous MDH), which indicated an almost 3- fold increase in the rate of catalytic conversion of oxaloacetate to malate in cells transfected with the exogenous cytMDH (Fig. 4).
EXAMPLE 4: G93A-hSODl upregulates cytMDH but decreases in vivo cytMDH activity
The impact of G93A-hSODl-GFP and WT-hSODl-GFP on expression of endogenous cytMDH was then assessed. Expression of endogenous cytMDH RNA in both G93A and WT hSODl-GFP lines before and after doxycycline induction (to induce expression of the hSODl-GFP proteins) is shown in Figure 5. Significant 2.4- fold up-regulation of cytMDH mRNA was observed following 48h of induction of expression of G93A-hSODl-GFP, while no increase was found after induction of WT-hSODl-GFP expression.
To evaluate whether endogenous cytMDH enzymatic activity is affected by the presence of G93A-hSODl, endogenous cytMDH activity was assessed in vitro in lysates from cells of the lines stably containing the inducible G93A-hSODl-GFP and
WT-hSODl-GFP with and without doxycycline treatment. The rate of conversion of oxaloacetate to malate in lysates of G93A-hSODl-GFP cells was only slightly (10%) increased compared to non-induced cells. The respective cytMDH activity in non- induced WT-hSODl-GFP cells was comparable to non-induced G93A-hSODl-GFP cells and did not change after induction of WT-hSODl expression (Fig 5).
Cell lactate and malate levels were next measured to evaluate the impact of G93A-hSODl on cytMDH activity in intact cells. It was believed that if cytMDH activity was inhibited, conversion of oxaloacetate to malate will be inhibited and thus malate levels will decrease. In addition, conversion of NADH to NAD+, which is coupled to this reaction, will thus occur through the alternative route, namely conversion of pyruvate to lactate, resulting in elevated lactate levels. Malate and lactate levels were thus assessed in stable lines expressing the inducible forms of
G93A-hSODl-GFP and WT-hSODl-GFP. Malate and lactate levels measured in these cells without (non-induced) or with 48 hours of treatment with doxycycline are depicted in Figure 6. Despite the increase in expression of the endogenous enzyme
(Fig 5), induction of expression of G93A-hSODl-GFP resulted in a significant increase in lactate and decrease in malate levels. No such effect was seen with the
WT-hSODl-GFP expressing cells. Notably, even in the non-induced state, G93A- hSODl-GFP cells had higher lactate and lower malate values compared to the cells expressing the WT-hSODl-GFP cells.
The effect of the change in efficiency of conversion of oxaloacetate to malate on NADH/NAD+ ratio in the cytosol and mitochondria was assessed in both cell lines with and without hSODl induction (Fig. 7). There were no significant differences in NADH/NAD+ in the cytosol between the non-induced G93A-hSODl-GFP and WT- hSODl-GFP cells. NADH/NAD+ ratio in the cytosol did not differ in induced compared to non-induced G93A-hSODl-GFP as well as WT-hSODl-GFP cells. However, in the mitochondria, the NADH/NAD+ ratio was significantly higher in the non-induced G93A-hSODl-GFP than in the WT-hSODl-GFP cells. A significant elevation in the mitochondrial NADH/NAD"1" ratio was found after a 48 hour- induction of expression of G93A-hSODl-GFP but not of WT-hSODl-GFP.
EXAMPLE 5: Identification of peptide agents that inhibit the formation of the complex between MDHl and mutant G93A-hSODl
Four plasmids were shown to express peptides that interacted with SODl. Of these, one corresponded to amino acids 14-27 of the cytMDH protein GQIAHSLLYSIGNG (SEQ ID NO: 2) and three corresponded to amino acids 217- 239 of the identified peptide corresponding to cytMDH protein SWLKGEFITTVQQRGAAVIKARK (SEQ ID NO: 1) (Figure 8). The restriction map of MDHl and the enzymes used for the library preparation are consistent with SEQ ID NO: 1 corresponding to nucleotides 745-807 in MDHl, namely the 66- nucleotide fragment 730-796.
The translated peptide, 217-239, having the sequence
SWLKGEFITTVQQRGAAVIKARK (SEQ ID NO: 1), is located at the MDHl surface, close to the MDHl dimerization site (Figure 8; peptide is highlighted in yellow, and monomeric units of MDHl are in blue and green. NADH is represented in stick-and-ball model).
Ability of the 217-239 peptide to disrupt the G93A-hSODl -cytMDH 1 complex was tested by co-transfection into NSC-34 cells of constructs encoding myc- tagged 217-239 and the FRET-enabled G93A-hSODl/cytMDH proteins, followed by FACS analysis to measure FRET. As shown in Figure 9, the 217-239 peptide blocked FRET, indicating disruption of the G93A-hSODl /cytMDH complex; compare (C) which contained the 217-239 peptide to (B) which lacked it. Cells transfected with constructs encoding G93A-hSODl-CFP and YFP were utilized as the negative FRET control (A), while cells co-transfected with constructs encoding G93A-hSODl-CFP /cytMDH- YFP and myc-tagged 14-27 peptide (D), found not to inhibit the interaction between the two proteins at 1 :1 :1 stoichiometry, served as a control for non-specific effects of the myc tag.
EXAMPLE 6: Inhibition of G93A-hSODl-cytMDH interaction improves cell survival in the presence of rotenone Materials and Experimental Methods
The SWLKGEFITTVQQRGAAVIKARK (SEQ ID NO: 1) peptide was synthesized (SBS Gentech Beijing) with 5,6-TAMRA modification (to allow detection) at the N-terminus, dissolved in 10% acetic acid, and diluted in cell culture medium containing 1% ethanol. Thus, 15,000 cells (WT-hSODl or G93A-hSODl) seeded in each well of 96 wells plate in DMEM, 10% serum and doxycline (to induce expression of the hSODl proteins). 24 hours later, medium was replaced with serum free DMEM, and cells were incubated with 1 micromol/liter of the TAMRA-labeled SWLKGEFITTVQQRGAAVIKARK peptide or vehicle (1% acetic acid/ethanol) for 4 hours. In some experiments, 0.5 micromol/L rotenone was then added and incubation resumed for 24 hours (Figure 10A). In other experiments, medium was replaced with low glucose (1 mg/ml) in DMEM with 5% serum with peptide or vehicle and incubation resumed for 72 hours (Figure 10B). Cell survival was then assessed.
Results
The effect of the 217-239 peptide on cell death induced by the mitochondrial inhibitor rotenone on cells expressing WT-hSODl-GFP and G93A-hSODl-GFP was assessed. It was expected that, if G93A-hSODl causes cell death by gain-of-toxic- interaction, this should exacerbate rotenone-induced death, and the exacerbation should be alleviated by inhibiting this interaction with the 217-239 peptide.
Expression of WT-hSODl or G93A-hSODl cells was induced with doxycline, after which medium was replaced with serum-free DMEM, and cells were incubated with 1 micromol/liter of TAMRA-S WLKGEFITTVQQRGAAVIKARK peptide or vehicle (1% acetic acid/ethanol), followed by addition of rotenone. Treatment with rotenone reduced cell viability to a greater extent in G93A-hSODl-GFP than WT- hSODl-GFP cells as measured by methylene blue assay (relative to the survival without rotenone). In the presence of the 217-239 peptide, the effects of rotenone were greatly diminished in the G93A-hSODl-GFP but not non-induced WT-hSODl- GFP lines (Figure 10A).
In other experiments, addition of peptide was followed by replacement of the media with low glucose (1 mg/ml) DMEM with 5% serum with peptide or vehicle. Low glucose levels reduced cell viability to a greater extent in G93A-hSODl-GFP than WT-hSODl-GFP cells, as measured by methylene blue assay (relative to the survival with normal glucose). In the presence of the 217-239 peptide, the effects of low glucose were significantly diminished in the G93A-hSODl but not non-induced WT-hSODl cell lines (Figure 10B).
These findings show that inhibition of G93A-hSODl-cytMDH interaction improves cell survival by inhibiting gain of this toxic interaction.
EXAMPLE 7: Gain of toxic interaction of G93A SODl-GFP is due to inhibition of the malate-aspartate shuttle The effects of octanoic acid on survival of rotenone- and low glucose challenged cells expressing WT-hSODl-GFP and G93A-hSODl-GFP were assessed (Figure 11). Treatment with rotenone (1.25 micromol/liter for 24h) reduced cell viability to a greater extent in G93A-hSODl-GFP than WT-hSODl-GFP expressing cells as measured by methylene blue assay (relative to the survival without rotenone). In the presence of octanoic acid, the effects of rotenone were greatly diminished in the G93A-hSODl-GFP but not non-induced WT-hSODl-GFP lines (Figure HA). Low glucose levels resulted in reduced cell viability to a greater extent in G93A-hSODl- GFP than WT-hSODl-GFP cells as measured by methylene blue assay (relative to the survival with normal glucose). In the presence of octanoic acid, the effects of low glucose were greatly diminished in the G93A-hSODl-GFP but not non-induced WT- hSODl-GFP lines (Figure HB). Thus, gain of toxic interaction of G93A SODl-GFP is due to inhibition of the malate-aspartate shuttle.
As provided herein, an interaction was identified, using novel FRET techniques in live motor-neuron derived cells, between mutant hSODl-GFP (disease protein) and BFP-tagged cytMDH, which does not occur with the wild type hSODl-GFP. Furthermore, using confocal microscopy close proximity was demonstrated between these proteins using a different pair of fluorophores and transient transfection into the parent NSC-34 cell line. Further interaction was demonstrated between BFP-tagged cytMDH and untagged mutant hSODl, which does not occur with untagged WT- hSODl in the cells using pull-down immunoprecipitation techniques. The tagged cytMDH retained MDH enzymatic activity, showing that its conformation was largely normal. Moreover, expression of the mutant protein affected expression of endogenous cytMDH (increase) and the levels of cell malate (decrease) and lactate (increase) as well as the NADH/NAD+ ratio in the mitochondria (increase), all of which are compatible with the consequences of inhibition of endogenous cytMDH by G93A-hSODl and are not seen with the WT-hSODl .
Malate dehydrogenases (MDH, L-malate:NAD oxidoreductase, EC 1.1.1.37), catalyze the NAD/NADH-dependent interconversion of malate and oxaloacetate in the cytoplasm (cytMDH) and mitochondria (MitMDH). This reaction plays a key part in the malate/aspartate shuttle between the cytoplasm across the mitochondrial membrane, and in the tricarboxylic acid cycle within the mitochondrial matrix. The association between the mutant hSODl with cytMDH may rely on structural properties of these proteins and imply that some structural properties of the mutant hSODl differ from those of the wild-type enzyme. This notion is compatible with the formation of aggregates and inclusion bodies by the mutant but not WT protein (3,17). Cytosolic MDH and mitMDH share a common catalytic mechanism and their kinetic properties are similar, which demonstrates a high degree of structural similarity (3). The specificity of the interaction between G93A-hSODl and cytMDH may thus be due to the preferential cytoplasmic localization of both.
Cytosolic MDH is a key enzyme in the malate-aspartate shuttle which is considered the most important shuttle in the brain and is particularly important in neurons. The malate-aspartate shuttle and the glycerol phosphate shuttle act to transfer reducing equivalents from NADH in the cytosol to the mitochondria, since the inner mitochondrial membrane is impermeable to NADH and NAD+ (18). Thus, in the cytoplasm, cytMDH converts oxaloacetate to malate, at the same time reoxidizing NADH in the cytosol to NAD+. Malate then enters the mitochondria in exchange for α-ketoglutarate. Mitochondrial MDH, which is part of the tricarboxylic acids (TCA) cycle enzyme, converts malate to oxaloacetate, at the same time reducing NAD+, forming equivalent amounts of NADH. This transfer of reducing equivalents is essential for maintaining a favorable NAD+/NADH ratio required for the oxidative metabolism of glucose and synthesis of neurotransmitters in brain. Inhibition of this shuttle thus impairs the utilization of glucose, which is a main source of metabolic energy in the neurons favoring the anaerobic option (formation of lactate) over the aerobic option (TCA cycle) and resulting in a lower ATP yield. Inhibition of the malate-aspartate shuttle has been shown to reduce consumption of oxygen in porcine carotid arterial strips (19), thus leading to ischemic conditions in the cells which are associated with increase in anaerobic conversion of pyruvate to lactate. Under such conditions, oxidative metabolism of pyruvate via the tricarboxylic acid (TCA) cycle, which would be more efficient in terms of ATP production, is diminished (18). Ischemic conditions increase mitochondrial NADH/NAD"1" ratio (20). The results of the studies presented herein are compatible with inhibition of cytMDH and consequently the malate-aspartate shuttle in cells expressing the mutant hSODl. Thus, malate levels decreased while lactate levels increased, confirming anaerobic conditions, and the mitochondrial NADH/NAD+ ratio increased accordingly. By this route, interaction between G93A-hSODl and cyt-MDH may reduce the maximal energy exploitation by the TCA cycle, thus shifting the cell towards anaerobic respiration and a state of hypoxia.
Another implication of inhibition of the malate-aspartate shuttle is an increase in reactive oxygen species (ROS) in mutant hSOD-expressing cells. The activity of α- Ketoglutarate dehydrogenase (α-KGDH), one of the key enzymes in the TCA cycle, is regulated by the NADH/NAD+ ratio. A higher NADH/NAD+ ratio induces a higher rate of H2O2 production by the enzyme. The observed increase in NADHTNAD+ ratio may thus promote α-KGDH-mediated ROS production (21). Increase in ROS has been shown to induce MDH expression (22). The up-regulation of cytMDH expression shown here in G93A-hSODl -expressing cells is thus consistent with elevated ROS in the cells. The fact that, despite upregulation of cytMDH expression, enzymatic activity was only slightly enhanced in these cells is compatible with inhibition of the enzyme activity by the mutant hSODl protein. It is interesting to note that even the non-induced G93A-hSODl cells had significantly higher levels of lactate and mitochondrial NADH/NAD+ ratio compared to the respective values in WT-hSODl cells. As with most inducible systems, there was about 10% leakage in expression of the mutant protein in the non-induced cells. Recent studies indicated that a low level of G93A-hSODl was sufficient to increase the production of ROS and to cause mitochondrial damage and death in NSC-34 cells (4). We thus assume that even a slight leak into expression of the inducible plasmid is sufficient to elicit some state of hypoxia in the G93A-hSODl cells.
Thus, the interaction between the mutant G93A-hSODl protein with cytMDH may result in inhibition of the malate-aspartate shuttle, leading to increased NADHTNAD+ ratio in the mitochondria. The latter results in inhibition of α-KGDH and elevates deleterious ROS production. Increase in ROS may inhibit the activity of HIF-lα-prolyl-4-hydroxylases (PHD) which acts to enhance the degradation of hypoxia induced factor lα (23). In addition, a decrease in the cytosolic PHD substrate α-Ketoglutarate might also lead to a decrease in PHD activity, resulting in an increase in HIF- lα. On the other hand, HIF- lα induces PHD expression thereby promoting its own degradation (24). Indeed, previous studies have demonstrated that neurons expressing G93A-hSODl are in a chronic state of hypoxia, as demonstrated in HIF- lα upregulation and the impaired hypoxia response in these cells (Mali & Zisapel unpublished). Thus, inhibition of the malate aspartate shuttle may, via modulation of PHD enzymatic activity, explain the dysregulation of cellular responses to hypoxia in the G93A-hSODl expressing cells. Another aspect of impaired malate-aspartate shuttle is the impairment in synthesis of neurotransmitters, particularly glutamate. The cytosolic aspartate aminotransferase converts aspartate to oxaloacetate, while simultaneously converting α-ketoglutarate into glutamate. Inhibition of the malate-aspartate shuttle significantly decreased the biosynthesis of neurotransmitter glutamate in synaptosomes (28). Abnormal glutamate metabolism has also been reported in ALS. Reduced glutamate levels have been reported in brain and spinal cord tissue of ALS patients (29). Glutamate dehydrogenase activity, which converts α-ketoglutarate to glutamate, was found to be decreased in leukocytes from ALS patients (30).
It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination.
Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims. All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention. 1. Carri, M. T., Ferri, A., Battistoni, A., Famhy, L., Gabbianelli, R., Poccia, F., and Rotilio, G. (1997) FEBS Lett 414, 365-368
2. Kruman, II, Pedersen, W. A., Springer, J. E., and Mattson, M. P. (1999) Exp Neurol 160, 28-39
3. Menzies, F. M., Cookson, M. R., Taylor, R. W., Turnbull, D. M., Chrzanowska-Lightowlers, Z. M., Dong, L., Figlewicz, D. A., and Shaw, P. J. (2002) Brain 125, 1522-1533
4. Rizzardini, M., Mangolini, A., Lupi, M., Ubezio, P., Bendotti, C, and Cantoni, L. (2005) J Neurol Sci 232, 95-103
5. Beal, M. F. (2000) Brain 123 ( Pt 7), 1291-1292
6. Bendotti, C, and Carri, M. T. (2004) Trends MoI Med 10, 393-400
7. Lambrechts, D., Storkebaum, E., Morimoto, M., Del-Favero, J., Desmet, F., Marklund, S. L., Wyns, S., Thijs, V., Andersson, J., van Marion, L, Al- Chalabi, A., Bornes, S., Musson, R., Hansen, V., Beckman, L., Adolfsson, R.,
Pall, H. S., Prats, H., Vermeire, S., Rutgeerts, P., Katayama, S., Awata, T., Leigh, N., Lang-Lazdunski, L., Dewerchin, M., Shaw, C, Moons, L., Vlietinck, R., Morrison, K. E., Robberecht, W., Van Broeckhoven, C, Collen, D., Andersen, P. M., and Carmeliet, P. (2003) Nat Genet 34, 383-394 8. Greenway, M. J., Andersen, P. M., Russ, C, Ennis, S., Cashman, S., Donaghy, C, Patterson, V., Swingler, R., Kieran, D., Prehn, J., Morrison, K. E., Green, A., Acharya, K. R., Brown, R. H., Jr., and Hardiman, O. (2006) Nat Genet 38, 411-413
9. Brockington, A., Wharton, S. B., Fernando, M., Gelsthorpe, C. H., Baxter, L., Ince, P. G., Lewis, C. E., and Shaw, P. J. (2006) J Neuropathol Exp Neurol 65,
26-36
10. Bruijn, L. L, Miller, T. M., and Cleveland, D. W. (2004) Annu Rev Neurosci 27, 723-749
11. Zhang, F., Strom, A. L., Fukada, K., Lee, S., Hayward, L. J., and Zhu, H. (2007) J Biol Chem
12. Chan, F. K. (2004) Methods MoI Biol 261, 371-382
13. Cashman, N. R., Durham, H. D., Blusztajn, J. K., Oda, K., Tabira, T., Shaw, I. T., Dahrouge, S., and Antel, J. P. (1992) Dev Dyn 194, 209-221 14. Zheng, J., Varnum, M. D., and Zagotta, W. N. (2003) J Neurosci 23, 8167- 8175
15. Bubis, M., and Zisapel, N. (1998) MoI Cell Endocrinol 137, 59-67
16. Shinder, G. A., Lacourse, M. C, Minotti, S., and Durham, H. D. (2001) J Biol Chem 276, 12791-12796
17. Takeuchi, H., Kobayashi, Y., Ishigaki, S., Doyu, M., and Sobue, G. (2002) J Biol Chem 277, 50966-50972
18. McKenna, M. C, Waagepetersen, H. S., Schousboe, A., and Sonnewald, U.
(2006) Biochem Pharmacol 71, 399-407 19. Barron, J. T., Gu, L., and Parrillo, J. E. (1998) J MoI Cell Cardiol 30, 1571- 1579
20. Zhou, L., Stanley, W. C, Saidel, G. M., Yu, X., and Cabrera, M. E. (2005) J Physiol 569, 925-937
21. Adam- Vizi, V. (2005) Antioxid Redox Signal 7, 1140- 1149 22. Hu, R., Jin, H., Zhou, S., Yang, P., and Li, X. (2007) Placenta 28, 399-407
23. Pan, Y., Mansfield, K. D., Beitozzi, C. C, Rudenko, V., Chan, D. A., Giaccia, A. J., and Simon, M. C. (2006) MoI Cell Biol
24. Marxsen, J. H., Stengel, P., Doege, K., Heikkinen, P., Jokilehto, T., Wagner, T., Jelkmann, W., Jaakkola, P., and Metzen, E. (2004) Biochem J 381, 761-767 25. Siciliano, G., Piazza, S., Carlesi, C, Del Corona, A., Franzini, M., Pompella, A., Malvaldi, G., Mancuso, M., Paolicchi, A., and Murri, L. (2007) J Neurol
26. Lederer, C. W., Torrisi, A., Pantelidou, M., Santama, N., and Cavallaro, S.
(2007) BMC Genomics 8, 26
27. Fergani, A., Oudart, H., Gonzalez de Aguilar, J. L., Fricker, B., Rene, F., Hocquette, J. F., Meininger, V., Dupuis, L., and Loeffler, J. P. (2007) J Lipid
Res
28. Palaiologos, G., Hertz, L., and Schousboe, A. (1988) J Neurochem 51, 317-320
29. Plaitakis, A., Constantakakis, E., and Smith, J. (1988) Ann Neurol 24, 446-449
30. Hugon, J., Tabaraud, F., Rigaud, M., Vallat, J. M., and Dumas, M. (1989) Neurology 39, 956-958
31. Van Westerlaak, M. G., Joosten, E. A., Gribnau, A. A., Cools, A. R., and Bar, P. R. (2001) Brain Res 922, 243-249
32. Kaal, E. C, Vlug, A. S., Versleijen, M. W., Kuilman, M., Joosten, E. A., and
Bar, P. R. (2000) J Neurochem 74, 1158-1165 3. Ramos, M., del Arco, A., Pardo, B., Martinez-Serrano, A., Martinez-Morales, J. R., Kobayashi, K., Yasuda, T., Bogonez, E., Bovolenta, P., Saheki, T., and Satrustegui, J. (2003) Brain Res Dev Brain Res 143, 33-46

Claims

1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as an active ingredient, an agent capable of preventing an interaction between malate dehydrogenase and a conformationally altered or mutant protein, wherein said mutant protein is associated with a neurodegenerative disorder.
2. The pharmaceutical composition of claim 1, wherein said neurodegenerative disorder is amyotrophic lateral sclerosis (ALS).
3. The pharmaceutical composition of claim 1 wherein said conformationally altered or mutant protein is a mutant SODl protein.
4. The pharmaceutical composition of claim 1, wherein said agent is a peptide agent.
5. The pharmaceutical composition of claim 4 wherein said peptide agent comprises at least 4-7 consecutive amino acids of human malate dehydrogenase.
6. The pharmaceutical composition of claim 4, wherein said peptide agent comprises SEQ ID NO: 1.
7. The pharmaceutical composition of claim 1, wherein said malate dehydrogenase protein is a cytosolic malate dehydrogenase (cytMDH) protein.
8. A method of treating a neurodegenerative disorder caused by complex formation of cytosolic malate dehydrogenase with a conformationally altered or mutant protein in a subject in need thereof, the method comprising administering to said subject a therapeutically effective amount of an agent capable of reducing an interaction between said cytosolic malate dehydrogenase and said conformationally altered or mutant neurodegenerative disease-causing protein, wherein said conformationally altered or mutant-causing protein is associated with said neurodegenerative disease, thereby treating a neurodegenerative disorder in a subject.
9. The method of claim 8, wherein said neurodegenerative disorder is amyotrophic lateral sclerosis (ALS).
10. The method of claim 8, wherein said conformational^ altered or mutant protein is a mutant SODl protein.
11. The method of claim 8, wherein said agent is a peptide agent.
12. The method of claim 11, wherein said peptide comprises at least 4 consecutive amino acids of human malate dehydrogenase.
13. The method of claim 11, wherein said wherein said peptide comprises SEQ ID NO: 1.
14. The method of claim 8, wherein said malate dehydrogenase is a cytosolic malate dehydrogenase (cytMDH).
15. A method of treating a neurodegenerative disorder, the method comprising administering to an individual in need thereof a therapeutically effective amount of an agent capable of increasing brain mitochondrial respiration, thereby treating the neurodegenerative disorder, with the proviso that said agent is not pyruate or oxaloacetate.
16. The method of claim 15, wherein said agent is capable of increasing cytoplasmic malate levels.
17. The method of claim 16, wherein said agent is a peptide agent.
18. The method of claim 15, wherein said peptide agent comprises at least 4-7 amino acids of human malate dehydrogenase.
19. The method of claim 18, wherein said peptide agent is as set forth in SEQ ID NO: 1.
20. The method of claim 15, wherein said agent is a small molecule.
21. The method of claim 20, wherein said small molecule is selected from the group consisting of maleate, octanoate, α-ketoglutarate, succinate and fumarate.
22. The method of claim 15, wherein said agent is capable of up-regulating an activity of malate dehydrogenase.
23. The method of claim 21, wherein said agent is capable of up-regulating acetyl coenzyme A.
24. The method of claim 15, wherein said malate dehydrogenase protein is a cytosolic malate dehydrogenase (cytMDH) protein.
25. A method of identifying an agent capable of treating ALS, the method comprising the steps of:
(a) contacting said agent with a known initial amount of a complex of malate dehydrogenase and a mutant SODl protein, wherein said mutant SODl protein is associated with amyotrophic lateral sclerosis (ALS); and (b) measuring an amount of said complex in the presence of said agent, whereby, if said amount of said complex in the presence of said agent is less than said known initial amount, then said agent is capable of treating amyotrophic lateral sclerosis.
26. The method of claim 25, wherein said complex is fluorescently labeled and the step of measuring an amount of said complex is performed by measuring a signal from said complex.
27. The method of claim 25, wherein said signal comprises FRET.
28. The method of claim 25, wherein said malate dehydrogenase protein is a cytosolic malate dehydrogenase (cytMDH) protein.
29. A method of identifying an agent capable of treating ALS, the method comprising the steps of:
(a) contacting a malate dehydrogenase protein with a mutant SODl protein, wherein said mutant SODl protein is associated with amyotrophic lateral sclerosis (ALS), in the presence of said agent; (b) measuring the amount of complex formation between said malate dehydrogenase protein and said mutant SODl protein, following step (a);
(c) contacting said malate dehydrogenase protein with said mutant SODl protein in the absence of said agent; and
(d) measuring the amount of complex formation between said malate dehydrogenase protein and said mutant SODl protein, following step (c), whereby, if said amount of step (b) is less than said amount of step (d), then said agent is capable of treating amyotrophic lateral sclerosis.
30. The method of claim 29, wherein said complex is fluorescently labeled and the step of measuring an amount of said complex is performed by measuring a signal from said complex.
31. The method of claim 30, wherein said signal comprises FRET.
32. The method of claim 29, wherein said malate dehydrogenase protein is a cytosolic malate dehydrogenase (cytMDH) protein.
33. A method of identifying an agent capable of treating a neurodegenerative disorder, the method comprising the steps of:
(a) contacting said agent with a known initial amount of a complex of malate dehydrogenase and a mutant protein, wherein said mutant protein is associated with said neurodegenerative disorder; and
(b) measuring an amount of said complex in the presence of said agent, whereby, if said amount of said complex in the presence of said agent is less than said known initial amount, then said agent is capable of treating said neurodegenerative disorder.
34. The method of claim 33, wherein said mutant protein is selected from the group consisting of mutant version of Alpha-synuclein, Parkin, PFNKl, DJ-I, ATPl 3 A2, amyloid beta peptide (ABETA), Huntingtin, androgen receptor, and microtubule-associated protein tau.
35. The method of claim 33, wherein said neurodegenerative disorder is selected from the group consisting of Parkinson's disease, Alzheimer's disease, Huntington disease, Kennedy disease, Pick's disease (PID), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP- 17).
36. The method of claim 33, wherein said complex is fluorescently labeled and the step of measuring an amount of said complex is performed by measuring a signal from said complex.
37. The method of claim 36, wherein said signal comprises FRET.
38. The method of claim 33, wherein said malate dehydrogenase protein is a cytosolic malate dehydrogenase (cytMDH) protein.
39. A method of identifying an agent capable of treating a neurodegenerative disorder, the method comprising the steps of: (a) contacting a malate dehydrogenase protein with a mutant protein, wherein said mutant protein is associated with said neurodegenerative disorder, in the presence of said agent;
(b) measuring the amount of complex formation between said malate dehydrogenase protein and said mutant protein, following step (a); (c) contacting said malate dehydrogenase protein with said mutant protein in the absence of said agent; and
(d) measuring the amount of complex formation between said malate dehydrogenase protein and said mutant protein, following step (c), whereby, if said amount of step (b) is less than said amount of step (d), then said agent is capable of treating said neurodegenerative disorder.
40. The method of claim 39, wherein said mutant protein is selected from the group consisting of mutant version of Alpha-synuclein, Parkin, PINKl, DJ-I, ATPl 3 A2, amyloid beta peptide (ABETA), Huntingtin, androgen receptor, and microtubule-associated protein tau.
41. The method of claim 39, wherein said neurodegenerative disorder is selected from the group consisting of Parkinson's disease, Alzheimer's disease, Huntington disease, Kennedy disease, Pick's disease (PID), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).
42. The method of claim 39, wherein said complex is fluorescently labeled and the step of measuring an amount of said complex is performed by measuring a signal from said complex.
43. The method of claim 42, wherein said signal comprises FRET.
44. The method of claim 39, wherein said malate dehydrogenase protein is a cytosolic malate dehydrogenase (cytMDH) protein.
PCT/IL2008/001351 2007-10-11 2008-10-12 Cytoplasmic malate dehydrogenase (mdh1) targeted treatment for neurodegenerative diseases WO2009047770A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP08837074A EP2180899A2 (en) 2007-10-11 2008-10-12 Cytoplasmic malate dehydrogenase (mdh1) targeted treatment for neurodegenerative diseases
US12/682,120 US8461297B2 (en) 2007-10-11 2008-10-12 Cytoplasmic malate dehydrogenase (MDH1) targeted treatment for neurodegenerative diseases
CN200880111245A CN101820897A (en) 2007-10-11 2008-10-12 Cytoplasmic malate dehydrogenase (MDH1) targeted treatment for neurodegenerative diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US97908007P 2007-10-11 2007-10-11
US60/979,080 2007-10-11
US7840108P 2008-07-06 2008-07-06
US61/078,401 2008-07-06

Publications (2)

Publication Number Publication Date
WO2009047770A2 true WO2009047770A2 (en) 2009-04-16
WO2009047770A3 WO2009047770A3 (en) 2009-07-16

Family

ID=40549696

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2008/001351 WO2009047770A2 (en) 2007-10-11 2008-10-12 Cytoplasmic malate dehydrogenase (mdh1) targeted treatment for neurodegenerative diseases

Country Status (4)

Country Link
US (1) US8461297B2 (en)
EP (1) EP2180899A2 (en)
CN (1) CN101820897A (en)
WO (1) WO2009047770A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010033045A1 (en) * 2008-09-16 2010-03-25 Igor Anatolievich Pomytkin Compositions and methods for prevention or treatment of beta amyloid deposition

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006073734A2 (en) 2004-12-01 2006-07-13 Whitehead Institute For Biomedical Research Modulator of alpha-synuclein toxicity
WO2006124892A2 (en) 2005-05-13 2006-11-23 Whitehead Institute For Biomedical Research Modulators of alpha-synuclein toxicity
WO2009086306A1 (en) 2007-12-21 2009-07-09 Whitehead Institute For Biomedical Research Modulators of alpha-synuclein toxicity
US20150328176A1 (en) * 2013-01-25 2015-11-19 Winning The Fight Inc. Composition for treatment of neurodegenerative disease
CN112029738B (en) * 2020-08-18 2022-04-29 浙江省人民医院 Human parkin protein acetylation and application thereof in medicine preparation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274138B1 (en) * 1997-09-03 2001-08-14 Incyte Genomics, Inc. Human mitochondrial malate dehydrogenase
WO2006066244A2 (en) * 2004-12-17 2006-06-22 Cash Alan B Method for extending lifespan and delaying the onset of age-related disease
EP1754485A1 (en) * 2004-04-08 2007-02-21 Tomohiro Chiba Remedy for neurodegenerative diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7834146B2 (en) * 2000-05-08 2010-11-16 Monsanto Technology Llc Recombinant polypeptides associated with plants

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274138B1 (en) * 1997-09-03 2001-08-14 Incyte Genomics, Inc. Human mitochondrial malate dehydrogenase
EP1754485A1 (en) * 2004-04-08 2007-02-21 Tomohiro Chiba Remedy for neurodegenerative diseases
WO2006066244A2 (en) * 2004-12-17 2006-06-22 Cash Alan B Method for extending lifespan and delaying the onset of age-related disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CARRI M. T. ET AL.: "Expression of a Cu,Zn superoxide dismutase typical of familial amyotrophic lateral sclerosis induces mitochondrial alteration and increase of cytosolic Ca<2+> concentration in transfected neuroblastoma SH-SY5Y cells" FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 414, no. 2, 8 September 1997 (1997-09-08), pages 365-368, XP004366349 ISSN: 0014-5793 cited in the application *
MALI Y ET AL: "Gain of interaction of ALS-linked G93A superoxide dismutase with cytosolic malate dehydrogenase" NEUROBIOLOGY OF DISEASE, BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD, GB, vol. 32, no. 1, 1 October 2008 (2008-10-01), pages 133-141, XP025425658 ISSN: 0969-9961 [retrieved on 2008-07-03] *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010033045A1 (en) * 2008-09-16 2010-03-25 Igor Anatolievich Pomytkin Compositions and methods for prevention or treatment of beta amyloid deposition

Also Published As

Publication number Publication date
US20100279943A1 (en) 2010-11-04
CN101820897A (en) 2010-09-01
US8461297B2 (en) 2013-06-11
EP2180899A2 (en) 2010-05-05
WO2009047770A3 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
Nowosad et al. p27 controls Ragulator and mTOR activity in amino acid-deprived cells to regulate the autophagy–lysosomal pathway and coordinate cell cycle and cell growth
Zhao et al. Apolipoprotein E4 impairs neuronal insulin signaling by trapping insulin receptor in the endosomes
Jao et al. ATF6α downregulation of PPARα promotes lipotoxicity-induced tubulointerstitial fibrosis
Imamura et al. RIPK3 promotes kidney fibrosis via AKT-dependent ATP citrate lyase
US11852634B2 (en) Use of AKT phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
Ghosh et al. Macroautophagy and chaperone‐mediated autophagy in heart failure: the known and the unknown
Watanabe et al. Cystatin C protects neuronal cells against mutant copper-zinc superoxide dismutase-mediated toxicity
Triani et al. Biliverdin reductase-A impairment links brain insulin resistance with increased Aβ production in an animal model of aging: implications for Alzheimer disease
Yoo et al. Protein disulfide-isomerase A3 significantly reduces ischemia-induced damage by reducing oxidative and endoplasmic reticulum stress
Wang et al. Parkin overexpression attenuates Aβ-induced mitochondrial dysfunction in HEK293 cells by restoring impaired mitophagy
Iwaki et al. Inhibition of methotrexate uptake via organic anion transporters OAT1 and OAT3 by glucuronides of nonsteroidal anti-inflammatory drugs
Miyazaki et al. DJ‐1‐binding compounds prevent oxidative stress‐induced cell death and movement defect in Parkinson’s disease model rats
WO2009047770A2 (en) Cytoplasmic malate dehydrogenase (mdh1) targeted treatment for neurodegenerative diseases
US20110287026A1 (en) Sirt4 and uses thereof
Yu et al. Coupling between neuronal nitric oxide synthase and glutamate receptor 6–mediated c-Jun N-terminal kinase signaling pathway via S-nitrosylation contributes to ischemia neuronal death
Wang et al. Upregulation of MDH1 acetylation by HDAC6 inhibition protects against oxidative stress-derived neuronal apoptosis following intracerebral hemorrhage
Fujiwara et al. Effects of the chemical chaperone 4-phenylbutylate on the function of the serotonin transporter (SERT) expressed in COS-7 cells
Chen et al. Pifithrin-alpha reduces methamphetamine neurotoxicity in cultured dopaminergic neurons
Kvirkvelia et al. Kidney-targeted inhibition of protein kinase C-α ameliorates nephrotoxic nephritis with restoration of mitochondrial dysfunction
Hu et al. Protective effects of curcumin on desipramine-induced islet β-cell damage via AKAP150/PKA/PP2B complex
Gao et al. Cr (VI) induced mitophagy via the interaction of HMGA2 and PARK2
Idera et al. Wild-type and pathogenic forms of ubiquilin 2 differentially modulate components of the autophagy-lysosome pathways
Venardos et al. Effect of peroxynitrite on endothelial L-arginine transport and metabolism
Gao et al. NDP52 SUMOylation contributes to low‐dose X‐rays‐induced cardiac hypertrophy through PINK1/Parkin‐mediated mitophagy via MUL1/SUMO2 signalling
Xie et al. A brain-specific isoform of apoptosis-inducing factor 2 attenuates ischemia-induced oxidative stress in HT22 cells

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880111245.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08837074

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008837074

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2319/DELNP/2010

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12682120

Country of ref document: US